Characterization of Human 82-kDa Choline Acetyltransferase expression in a newly developed Transgenic Mouse Model by Vanvaerenbergh, Silke M
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
8-15-2014 12:00 AM 
Characterization of Human 82-kDa Choline Acetyltransferase 
expression in a newly developed Transgenic Mouse Model 
Silke M. Vanvaerenbergh 
The University of Western Ontario 
Supervisor 
Dr. Jane Rylett 
The University of Western Ontario 
Graduate Program in Physiology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Silke M. Vanvaerenbergh 2014 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Molecular and Cellular Neuroscience Commons 
Recommended Citation 
Vanvaerenbergh, Silke M., "Characterization of Human 82-kDa Choline Acetyltransferase expression in a 
newly developed Transgenic Mouse Model" (2014). Electronic Thesis and Dissertation Repository. 2193. 
https://ir.lib.uwo.ca/etd/2193 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
  
 
 
 
CHARACTERIZATION OF HUMAN 82-KDA CHOLINE ACETYLTRANSFERASE 
EXPRESSION IN A NEWLY DEVELOPED TRANSGENIC MOUSE MODEL 
Thesis Format: Monograph 
 
 
By 
 
Silke M. Vanvaerenbergh 
 
Graduate Program in Physiology and Pharmacology 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of  
Master of Science 
 
The School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada 
 
 
© Silke M. Vanvaerenbergh, 2014 
  
  
ii 
 
ABSTRACT  
 
Expression of human 82-kDa choline acetyltransferase (ChAT) protein in nuclei of 
cultured neurons from Alzheimer’s disease model APP/PS1 transgenic mice results in a 
reduction in Aβ release, suggesting a protective role. This thesis characterizes the expression of 
human 82-kDa ChAT in 82-hChAT;NkCre transgenic mice by PCR-based examination of 
genomic DNA and localization of the protein in mice brains. First, I demonstrate in a cultured 
cell model that Cre recombinase-mediated excision of a floxed LacZ gene is necessary for 
human 82-kDa ChAT protein expression from pcCALL2:82-ChAT, the plasmid used to create 
founder transgenic mice. Second, I confirmed that human 82-kDa ChAT protein is expressed in 
the brain of 82-hChAT;NkCre but not 82-hChAT mice. This protein is localized to nuclei of 
neurons in the basal forebrain and medial cerebral cortex. These findings indicate that we 
successfully generated transgenic mice that have neuron-specific expression of human 82-kDa 
ChAT protein in Nkx2.1-Cre driven areas.  
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CHAPTER 1: INTRODUCTION 
 
1.  Cholinergic Neurons 
 
Overview 
 
Cholinergic neurotransmission is essential in the regulation of a number of 
physiological processes throughout the central and peripheral nervous systems. 
Cholinergic neurons are nerve cells that have the necessary components to synthesize, 
store and release the neurotransmitter acetylcholine (ACh) at their presynaptic terminals. 
ACh, which was first described in 1921 by Loewi (Loewi 1921), is used to communicate 
information at the skeletal neuromuscular junction, and in the autonomic nervous system 
at all pre- and post-ganglionic parasympathetic synapses and at pre-ganglionic 
sympathetic synapses. The role of ACh and cholinergic neurons in the central nervous 
system is widespread and includes involvement in attention, memory, learning, arousal, 
sleep and cognition to name a few processes (Sarter & Parihk 2005, Hasselmo 2006, 
Woolf & Butcher 2011). Several neuropathological diseases are associated with 
cholinergic neuron dysfunction including Alzheimer’s, Parkinson’s and Huntington’s 
diseases as well as amyotrophic lateral sclerosis (ALS) and schizophrenia (Bartus et al. 
1982, Kato 1989, Nance et al. 1996, Harrison 1999, Oda 1999).  
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Cholinergic Neurochemistry: Synthesis, Storage, Release and Degradation of ACh 
 
The key players in the production and degradation of ACh are the catalytic 
enzyme choline acetyltransferase (ChAT), the hemicholinium-sensitive, sodium-
dependent, high-affinity choline transporter (CHT) that delivers the substrate choline into 
cholinergic presynaptic terminals, the vesicular acetylcholine transporter (VAChT) that 
transports ACh into synaptic vesicles for storage with its release stimulated by an action 
potential and acetylcholinesterase (AChE) that hydrolyzes ACh into choline and acetate. 
The rate of ACh synthesis is determined by the availability of its co-substrates 
acetyl Coenzyme A and choline, with choline availability being the rate-limiting step for 
ACh production under most conditions (Tucek 1993). Choline is not produced de novo in 
neurons but rather is derived from the diet and by phospholipase C-mediated hydrolysis 
of plasma membrane phosphatidylcholine (Lee et al. 1993, Loffelholz 1998). Choline can 
be taken up into cells from the extracellular environment by two separate solute transport 
systems that are located at the plasma membrane. The first of these is the ubiquitous low-
affinity choline transporter that is expressed in all cells, with most of the choline taken up 
by this route converted into the plasma membrane component phosphatidylcholine. The 
second pathway is through the high-affinity transporter (CHT) that is expressed almost 
exclusively in cholinergic neurons and localized to cholinergic presynaptic terminals 
(Misawa et al. 2001, Ferguson et al. 2003). Choline uptake by this transporter is the rate-
limiting and regulatory step in ACh synthesis (Ribeiro et al. 2006). 
Following the uptake of choline into cholinergic presynaptic terminals, the 
synthesis of ACh occurs in the cytoplasm where ChAT catalyzes the conversion of 
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choline and acetyl-CoA to ACh (Blusztajn & Berse 2000). ACh is then packaged into 
synaptic vesicles by VAChT which is an amine/proton antiporter that is dependent on a 
proton gradient generated in synaptic vesicles (Whittaker 1998, Prado et al. 2002). 
Neuronal depolarization is responsible for leading to calcium-dependent release of ACh 
into the synaptic cleft (Ehret et al. 2001). Following the exocytotic release of ACh from 
synaptic vesicles, it can bind to and activate either muscarinic ACh receptors (mAChR) 
or nicotinic ACh receptors (nAChR) located on the pre- or post-synaptic neurons (Gotti 
et al. 2009). Ultimately, ACh is hydrolyzed by AChE with generation of acetate and 
choline, thus providing a pool of choline that is transported back into cholinergic pre-
synaptic terminals by CHT (Blusztajn & Berse 2000). Synaptic vesicles that previously 
released ACh are recycled back into the nerve terminal where they can be refilled with 
neurotransmitter that can then be released into the synaptic cleft upon neuronal 
depolarization by subsequent action potentials (Smith et al. 2008). 
 
ACh Signalling 
 
As mentioned previously, ACh can bind to and activate two types of receptors: 
nicotinic ACh receptors (nAChR) and muscarinic ACh receptors (mAChR). nAChRs are 
ligand-gated ion channels that are permeable to Na
+
, K
+ 
and Ca
2+
, and mAChRs are G-
protein coupled receptors (Blusztajn & Berse 2000).  
nAChRs, which have an approximate total molecular mass of 290 kDa, are made 
up of 5 protein subunits arranged around a central pore (Unwin 2005). These pentamers 
are made up of a number of combinations of α, β, δ, ε and γ subunits. Neuronal nAChRs 
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are predominantly comprised of only the α7 subunit or the α4 and β2 subunits, while 
muscular nAChRs contain two α subunits and one of each of β, δ, and ε/γ (Itier & 
Bertrand 2001, Albequerque et al. 2009). Pre-synaptically, nAChRs modulate 
neurotransmitter release and post-synaptically, the nAChRs mediate fast synaptic 
transmission such as that needed to affect muscle contraction at the neuromuscular 
junction (Dajas-Bailador & Wonnacott 2004).  
As with nAChRs, mAChRs are found both pre- and post-synaptically. They fall 
into 5 subtypes referred to as M1-M5 which are under 2 subclasses: the M1 subclass 
containing M1, M3 and M5 receptors and the M2 class containing M2 and M4 receptors 
(Caulfield & Birdsall 1998). The M1 subclass is coupled to Gq class of G proteins and 
uses the upregulation of phospholipase C to increase inositol triphosphate and 
intracellular calcium as signalling pathways (Burford & Nahorski 1996). The M2 
subclass of mAChRs acts via Gi type G proteins that cause a decrease in cAMP through 
inhibition of adenylate cyclase, leading to inhibition of voltage-gated Ca
2+
 channels 
(Dell’Acqua et al. 1993). 
 
Localization of Cholinergic Neurons in the CNS 
 
Initially, immunohistochemical (IHC) studies used AChE as a marker to identify 
cholinergic neuron location within the brain, but it was found that AChE is not specific 
for cholinergic neurons and is also found in cholinoceptive cells and other neurons 
(Mizukawa et al. 1986, Lysakowshi et al. 1989). Subsequently, studies were directed 
toward the production and use of antibodies that recognize cholinergic neuron phenotypic 
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proteins such as ChAT, CHT and VAChT. Studies of monkey and rodent brains revealed 
8 major groups of ChAT-immunoreactive neurons designated as Ch1-Ch8. These 8 
groups of neurons have been used to describe human central cholinergic systems as well. 
In humans, Ch1 comprises neurons associated with the medial septum, Ch2 and Ch3 with 
the diagonal band of Broca, Ch4 with the nucleus basalis of Meynert, Ch5 with the 
pedunculopontine tegmental nucleus, Ch6 with the laterodorsal tegmental nucleus, Ch7 
with the medial habenular nucleus and Ch8 with the parabigeminal nucleus. Some cranial 
nerve nuclei and the anterior horn of the spinal cord also contain ChAT-immunopositive 
neurons (Mizukawa et al. 1986, Mesulam & Geula 1988, Mesulam 1990). While early 
IHC studies did not reveal cholinergic neurons in the cerebral cortex (Armstrong 1983, 
Woolf 1991), it has now been demonstrated that there are ChAT-immunoreactive neurons 
present in cerebral cortex in rat, cat and human (Umbriaco et al. 1994, Avendaño et al. 
1996, Kasashima et al. 1999). More recently, investigations that have used in situ 
hybridization (ISH) to detect ChAT mRNA provide support for the previous IHC results, 
although some discrepancies do exist (Mesulam et al.1983, Kasashima et al. 1998, Oda 
1999). 
 
Projections and Pathways of Cholinergic Neurons in the Mammalian Brain  
 
Cholinergic neurons innervate almost all brain areas and mediate a range of 
physiological functions. Cholinergic systems of the mammalian brain include motor 
neurons in the spinal cord and hindbrain, a group of neurons in the medial habenula, 
cholinergic projection neurons in the basal forebrain and mesopontine region, and 
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interneurons in the striatum, olfactory tubercule and islands of Calleja complex 
(Armstrong et al. 1983, Semba & Fibiger 1989, Woolf 1991, Butcher & Woolf 2004, 
Woolf & Butler 2011). Figure 1 shows an image of the cholinergic neuron projections in 
the rodent brain. 
 
Figure 1. Cholinergic neuron projections in the mouse brain. There are two groups of 
cholinergic neurons in the basal forebrain. The medial septum group [medial septal 
nucleus (ms) and vertical diagonal band (vdb)] project axons to the hippocampus and the 
parahippocampal gyrus. The second group [nucleus basalis (bas), substantia innominata 
(si) and horizontal diagonal band (hdb)] project axons to the neocortex, parts of the 
limbic system and the amygdala. Pedunculopontine tegmental nuclei (ppt) and 
laterodorsal tegmental nuclei (ldt) project onto hindbrain, thalamus, hypothalamus and 
basal forebrain. This Figure is taken from Woolf NJ (1991).   
 
Cholinergic motor neurons. Cholinergic motor neurons innervate skeletal, 
smooth or cardiac muscle, as well as many glands. These neurons are highly organized 
into networks of clustered neurons and bundled fibres (Barber et al. 1984, Woolf 1991). 
There is a high degree of connectivity between cholinergic neurons and interneurons, and 
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it is these integrated networks that are important for coordinated muscle activity. ACh 
plays a role as chemical transmitter at the neuromuscular junction, but spinal cord 
neurons are also dependent on the presence of ACh during embryonic development for 
their initial configuration (Myers et al. 2005).  
Cholinergic neurons in the basal forebrain. The cholinergic basal forebrain has 
widespread projections to the entire neocortex and the forebrain limbic system. The 
forebrain can be divided into three distinct regions. The septohippocampal pathway 
projects to the hippocampus and the dendate gyrus from the medial septal nucleus and the 
vertical diagonal band nucleus (Wainer et al. 1985, Woolf et al. 1990, Woolf & Butcher 
2011). The intermediate area, which consists of the horizontal diagonal band nucleus and 
magnocellular preoptic nucleus projects to the olfactory bulb, amygdala, parts of the 
frontal cortex and the cingulate, retrosplenial, entorhinal, perirhinal and insular cortices 
(Saper 1984, Woolf et al. 1990, Woolf & Butcher 2011). Lastly, cholinergic neurons in 
the substantia innominata, magnocellular preoptic nucleus and nucleus basalis of Meynert 
project to all parts of the neocortex including primary and secondary visual, auditory and 
somatosensory and higher association cortex (Bigl et al. 1982, Woolf & Butcher 2011). 
Cholinergic basal forebrain neurons play critical roles in learning, memory, selective 
attention, perception and consciousness (Woolf 1998, Sarter et al. 2003).  
Cholinergic neurons in the medial habenula. Small, dorsally located cholinergic 
neurons of the medial habenula function in the regulation of electroencephalographic 
patterns and rapid eye movement sleep (Semba & Fibiger 1992). The dorsal location of 
the medial habenula is an exception to the rule that cholinergic neurons are located in 
ventral or basal structures (Woolf & Butler 2011).  
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Cholinergic neurons in the mesopontine region. Located in the laterodorsal 
tegmental nucleus and the pedunculopontine tegmental nucleus, cholinergic neurons of 
the mesopontine area innervate the spinal cord, brainstem, thalamus, hypothalamus, basal 
forebrain and the medial frontal cortex (Rye et al. 1984, Woolf & Butcher 1986). 
Consciousness and cognitive functions such as attention are mediated by ascending 
projections while descending cholinergic projections from the mesopontine region are 
involved with decreasing muscle tone during REM sleep (Shiromani et al. 1990, Bosch & 
Schmid 2008, Rostron et al. 2009, Woolf & Butler 2011). 
Cholinergic interneurons in the striatum. The striatum corresponds to the 
caudate nucleus-putamen complex, the nucleus accumbens and the islands of Calleja. 
Tonic activation of cholinergic interneurons in the striatum demonstrates the capacity to 
integrate motivational state with behaviour (Kimura et al. 2003).  
Cholinergic neurons in the cerebral cortex. In rodent brain, ChAT-positive 
fibres and terminal-like structures are distributed in a loose network throughout the cortex 
(Houser et al. 1984). Many of these fibres are presumed to originate from subcortical 
cholinergic neurons. ChAT-positive fibres are found to be rather evenly distributed 
throughout all layers of the motor cortex, but in a laminar pattern in the somatic sensory 
cortex. ChAT-positive neuronal soma are present throughout cortical layers II-VI, with 
the most concentrated areas being layers II and III. These cell bodies are bipolar in form 
and small in size with vertically oriented dendrites that span several cortical layers 
(Houser et al. 1984). However, it appears that ChAT-positive fibres and soma are absent 
in human cortices, indicating that there is variation among species (Mesulam 1990). 
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2. Dysfunction of Cholinergic Neurons 
 
As indicated above, neurochemical transmission by cholinergic neurons plays an 
important role in many peripheral and central nervous system processes. Dysfunction of 
cholinergic transmission is present in several neurological and psychiatric diseases 
including Alzheimer’s disease (Oda 1999, Mesulam 2004, Schliebs & Arendt 2011).  
 
Cholinergic Neuron Systems in Aging 
 
The basal forebrain, comprising of the medial septum, horizontal and vertical 
diagonal bands of Broca and the nucleus basalis of Meynert provide the major 
cholinergic projections to the cerebral cortex and the hippocampus. Cholinergic neurons 
associated with the basal forebrain undergo degenerative changes in aging, resulting in 
decreased function. This cholinergic hypofunction is related to memory deficits that are 
seen with increasing age (Schliebs & Arendt 2006, Schliebs & Arendt 2011). Normal 
aging is accompanied by dendritic, synaptic and axonal degeneration without the loss of 
cell bodies, suggesting that the loss of function associated with aging does not result from 
cell loss but rather from other mechanisms that may include decreased gene expression, 
impaired intracellular signalling, or decreased sensitivity of aging cholinergic neurons to 
nerve growth factor (NGF) (Katoh-Semba et al. 1998, Schliebs and Arendt 2011). NGF is 
believed to protect and maintain cholinergic neurons in the basal forebrain by improving 
neuronal survival, increasing sprouting of cholinergic neurons, and can rescue cholinergic 
cells from lesion-induced atrophy (Dekker et al.1991, Wilcox et al. 1995).  
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As well as displaying a decreased sensitivity to NGF, aging cholinergic neurons 
appear to have increased vulnerability to changes in the brain microenvironment. 
Cholinergic neurons in the basal forebrain, as compared to the striatum and brain stem, 
are especially vulnerable to toxic agents such as aluminum, nitric oxide and ethanol 
(Schliebs & Arendt 2011). Cholinergic cells also appear to have a higher demand for 
energy production. In this regard, acetyl-CoA is not only utilized for energy, but it is also 
required as a co-substrate for ACh synthesis, and therefore these neurons are more 
sensitive to age-related glucose deprivation (Szutowicz et al. 2006).  
 
Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is a neurological disorder and is characterized by 
cognitive deficits and decreases in attentional processing. Among people over the age of 
65, AD is the leading cause of dementia, accounting for about 50-80% of cases. A large 
literature documents several changes in cholinergic neuron function during the course of 
AD, including reductions or altered activity of a number of cholinergic markers including 
ChAT, AChE, mAChR, nAChR, CHT and levels of ACh. Interestingly, there have been 
reports of increased levels or activity of ChAT in some brain areas of individuals with 
mild cognitive impairment (MCI) or early AD, suggesting that there may be a phase of 
plasticity of cholinergic neurons in an attempt to restore or maintain function (Dekosky et 
al. 2002, Ikonomovic et al. 2003). The mechanisms underlying this or the role that this 
may play in the natural history of the disease are not well understood at present.  
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In AD, cholinergic neuron dysfunction is partnered with the extracellular 
accumulation of oligomeric β-amyloid peptides (Aβ) or the formation of amyloid plaques 
and the formation of neurofibrillary tangles in hippocampal and cortical neurons. It is 
thought that oligomeric Aβ can alter neurochemical function and induce 
neurodegenerative changes at cholinergic nerve terminals (Auld et al. 2002, Schliebs et 
al. 2011). Research surrounding the role of Aβ in AD has not yet fully elucidated the 
relationship between cholinergic dysfunction and Aβ, but it is clear that cholinergic 
neurons regulate amyloid precursor protein (APP) processing in target cells (Jiang et al. 
2012) and, in turn, Aβ alters cholinergic function by decreasing ACh synthesis and 
release (Kar et al. 2004).  
 
3. The Cholinergic Gene Locus 
 
As stated previously, ACh is synthesized in the cytoplasm of cholinergic nerve 
terminals by ChAT and is then stored in synaptic vesicles until release, with VAChT 
being responsible for transporting ACh from cytoplasm into vesicles (Oda 1999). 
Interestingly, it was discovered in 1994 that the entire open reading frame of VAChT is 
encoded by a single exon within the first intron of the ChAT gene (Bejanin et al. 1994). 
Thus, the configuration for the genes for these two cholinergic proteins has been termed 
the Cholinergic Gene Locus (Erickson et al. 1994), as illustrated schematically in Figure 
2. It has been thought that since components of the gene promoters for ChAT and 
VAChT are shared, then expression of these two proteins may be coordinated (Mallet et 
al. 1998). Indeed ChAT and VAChT are co-expressed in cholinergic neurons and their 
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expression is often co-regulated by physiological conditions and factors (Ichikawa et al. 
1997).  
ChAT is conserved throughout evolutionary development. The first cDNA for 
ChAT was cloned from Drosophila and subsequently the cloning of ChAT cDNA from 
rat, mouse, human, bird and C. elegans was also achieved (Slemmon et al. 1982, Ishii et 
al. 1990, Oda et al. 1992, Alfonso et al. 1994). Wu and Hersh (1994) revealed that there 
is a high degree of sequence homology between rat, mouse and human ChAT.  
The gene for human ChAT is found on chromosome 10 at position 10q11.2-10 
(Cohen-Haguenauer et al. 1990, Cervini et al. 1991). Multiple transcripts of this gene are 
generated through alternative splicing and differential utilization of non-coding exons in 
the gene promoter. In humans, at least 7 transcripts have been identified and named, R1-, 
R2-, N1-, N2-, M-, H- and S- types (Oda et al. 1992, Ohno et al. 2001). Importantly, in 
primates only, both the M-ChAT and S-ChAT transcripts encode an additional in-frame 
ATG start codon located in a favourable context for translation initiation that are not 
present in other species such as pig, rat and mouse (Oda et al. 1992). This allows for the 
production of two separate ChAT proteins of different apparent molecular masses from a 
single transcript. Thus, in all species, all ChAT transcripts encode the common 69-kDa 
protein (Wu and Hersh 1994), while in primate only, the M-transcript encodes an 
additional 82-kDa ChAT protein (Oda et al. 1992) and the S-transcript encodes an 
additional 74-kDa ChAT protein (Ohno et al. 2001). As these additional translation 
initiation sites are upstream of the normal ATG, they result in the production of larger 
forms of ChAT proteins that contain amino terminal extensions. In the case of 82-kDa 
ChAT, the protein shares structural identity with 69-kDa ChAT, but has a 118 residue 
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amino-terminal extension. It is the 82-kDa ChAT protein that is the subject of 
investigation in this thesis.  
 
Figure 2. The Cholinergic Gene Locus. The Cholinergic Gene Locus contains the 
coding sequence for multiple ChAT exons and the vesicular ACh transporter (VAChT). 
Alternative splicing leads to multiple transcripts of the ChAT gene. In primates only, the 
M-ChAT transcript has two functional initiation sites that can result in the production of 
two separate ChAT proteins with apparent molecular masses of 69-kDa and 82-kDa. The 
82-kDa ChAT protein is identical to the 69-kDa ChAT protein, except that it has the 
addition of a 118 residue extension at its amino terminus. 
 
Differential subcellular localization of ChAT 
 
Our laboratory was the first to demonstrate that 69-kDa ChAT and 82-kDa ChAT 
reside in different subcellular compartments. This was identified initially by visualizing 
enhanced green fluorescent protein (eGFP)-tagged ChAT protein expressed 
heterologously in neuronal cells by confocal microscopy (Resendes et al. 1999, Gill et al. 
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2003). The 82-kDa ChAT protein was found to be concentrated within the nucleus of 
cells, whereas the 69-kDa ChAT protein was found to be a nucleocytoplasmic shuttling 
protein that was localized predominantly in the cytoplasm (Gill et al. 2003).  
Nuclear localization sequence (NLS) motifs are rich in basic amino acid residues, 
such as lysine and arginine, and are required to mediate the selective transport of proteins 
from the cytoplasm into the nucleus. Analysis of the amino acid sequence of the 82-kDa 
ChAT reveals the presence of several basic residues within the first nine residues of the 
protein and this was confirmed to have functional NLS activity (Resendes et al. 1999). 
When these residues of 82-kDa ChAT were deleted and this mutant was expressed in 
HEK 293 cells, the resulting ChAT protein was no longer localized to the nucleus. Thus, 
it appears that these amino terminal basic residues have NLS function that is necessary 
and sufficient for 82-kDa ChAT to be transported into and retained in the nucleus.  
Importantly, our laboratory subsequently showed that the 82-kDa ChAT protein is 
expressed in necropsy human brain and spinal cord, using an antibody specific to the 
unique 82-kDa ChAT amino terminus (Gill et al. 2007). It was also shown that an age-
related difference in the subcellular localization of 82-kDa ChAT is seen in cholinergic 
motor neurons from the spinal cord. In younger subjects, 82-kDa ChAT staining is 
predominantly nuclear; however, this localization pattern changes to be both nuclear and 
cytoplasmic in neurons of older patients. Analysis of subcortical brain regions, such as 
the basal forebrain and putamen revealed similar age-related changes in subcellular 
localization of 82-kDa ChAT. Another novel finding of this study is the presence of 82-
kDa ChAT immunopositive neurons in the claustrum, an area not previously shown to 
contain ChAT-expressing neurons. While the regional and subcellular localization pattern 
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of staining for 69-kDa ChAT and 82-kDa ChAT did not differ substantially in MCI or 
early AD subjects as compared to older cognitively-intact subjects examined, age-related 
decline in staining of both ChAT proteins was evident in moderate to severe AD (Gill et 
al. 2007). 
While the role of 82-kDa ChAT in the nucleus has not yet been elucidated, data 
related to aspects of its significance are beginning to emerge (Albers et al. 2014). Our 
laboratory has shown, through use of microarray, that genes for several proteins that 
regulate amyloid precursor protein (APP) processing along both the amyloidogenic and 
non-amyloidogenic pathways are differentially expressed in 82-kDa ChAT containing 
cells. Specifically, a significant decrease in β-secretase (BACE1), one of the enzymes 
involved in the APP cleavage to toxic Aβ, and a reduction in the release of endogenous 
Aβ is seen when human 82-kDa ChAT protein is expressed in cortical neurons cultured 
from brains of AD model APP/PS1 transgenic mice (Albers et al. 2014). Nuclear 82-kDa 
ChAT may also be playing other roles in neurons such as acetylating nuclear substrates, 
binding to DNA and participating in nuclear events such as regulation of gene expression 
or it may simply serve as a reservoir of precursor enzyme with proteolytic cleavage 
resulting in the smaller 69-kDa form of ChAT (Resendes et al. 1999).  
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4. Transgenic Mouse Models 
 
Transgenic mice have altered genomes mediated through the use of genetic 
engineering techniques, and are useful animal models for the investigation of human 
diseases. Genetically-modified mouse models have been used to characterize different 
components of the cholinergic system through the use of null, heterozygous or over-
expression of genes. Mice are exceptional animal models as they are amendable to 
targeted gene modifications, share complex genome and neuroanatomical organization of 
mammals and can recapitulate some aspects of human diseases (Gaveriaux-Ruff & 
Kieffer 2007).  
 
The Cre-LoxP System 
 
Conditional gene knockout is a powerful approach in the study of the function of 
single genes in the nervous system or other tissues. Through the use of the Cre-LoxP 
system, it is possible to study both spatial and temporal genetic inactivation (Gaveriaux-
Ruff & Kieffer 2007). This technique was first described by Rajewski and coworkers and 
used to knockout the DNA polymerase beta gene in T lymphocytes (Gu et al. 1994). A 
similar approach was used to discover the role of N-methyl-D-aspartate (NMDA) 
receptor type 1 subunit in learning and memory processes, which lead to the discovery 
that there is strong genetic evidence for a correlation between NMDA, hippocampal long-
term potentiation and spatial learning (Gaveriaux-Ruff & Kieffer 2007). The targeting of 
the gene in hippocampus lead to the development of cell- and regional-specific knockouts 
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to study gene function in behaviours, neurological disorders and psychiatric diseases 
(Gaveriaux-Ruff & Kieffer 2007). In this way, the Cre-LoxP system is a valuable tool.  
 
The Cre Mouse 
 
Cre recombinase is an enzyme that is isolated from bacteriophage P1 that 
catalyzes recombination between two 34 base pair loxP sites in genomic DNA 
(Gaveriaux-Ruff & Kieffer 2007). The action of Cre recombinase depends on the 
orientation of the loxP sites. If the loxP sites are located in opposite directions, Cre 
recombinase mediates the inversion of the floxed segment. If loxP sites are located on 
different chromosomes, there is mediation of a chromosomal translocation. Finally, if the 
loxP sites are oriented in the same direction, the action of Cre recombinase results in an 
irreversible excision of DNA that resides between the two loxP sites. 
An important feature of the Cre recombinase system is that the Cre-mediated 
excision of DNA will occur in specific cell types or regions of the animal depending on 
the promoter that is used to drive Cre recombinase expression. Thus, cell- and tissue-
specific expression of Cre can be generated and used to yield either the cell- and tissue-
specific deletion of proteins of interest or expression of transgenic proteins of interest. 
Many transgenic Cre mouse lines have been established to be used as tools to facilitate 
regional and temporal control of protein expression (Gaveriaux-Ruff & Kieffer 2007).  
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Creation of a transgenic mouse 
 
The creation of a new transgenic mouse model begins with homologous 
recombination in embryonic stem cells to create a mouse with the “floxed” gene and 
other transgenic sequences incorporated into the mouse genome. The resulting mouse 
will have the gene of interest to be removed (LacZ in this case) flanked by 2 loxP sites. 
The loxP sites are strategically placed so that they will not disturb gene transcription 
(Gaverieaux-Ruff & Kieffer 2007).  
The Cre mouse is created through pronuclear injection and results in a mutant 
mouse that expresses Cre recombinase under the control of a specifically chosen 
promoter that will help determine the effects of cell- or regional-specific Cre expression. 
Cre recombinase expression in these mice can be determined through the incorporation of 
a reporter (for example, LacZ/β-Galactosidase or GFP) that can be assayed to further 
confirm that the recombination has occurred (Gaverieaux-Ruff & Kieffer 2007).  
The LoxP-expressing mouse is bred with the Cre mouse that will lead to the 
excision of the floxed gene in cells that are expressing Cre recombinase under the control 
of a specific promoter. The promoter used to drive Cre expression in the studies 
described in this thesis is the Nkx2.1 promoter.  
 
Nxk2.1  
 
Nkx2 homeobox 1 (Nkx2.1) is also known as thyroid transcription factor 1 (TTF-
1) and is a protein that regulates transcription of genes specific for thyroid, lung and parts 
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of the brain (Pan et al. 2004). In the brain, it is a transcription factor that is essential for 
pre-natal development, particularly of forebrain neurons, while postnatal expression of 
Nkx2.1 is essential for maturation and maintenance of cholinergic basal forebrain 
neurons (Magno et al. 2011).  
In the embryonic mouse lung, Nkx2.1 is expressed in a select group of foregut 
endodermal cells that form lung primordium around E9.5. In terms of fetal and post-natal 
lungs Nkx2.1 is confined to the type II alveolar epithelial cells and bronchiolar epithelial 
Clara cells (Pan et al. 2004). Expression of Nkx2.1 in the thyroid becomes detectable in 
the primordium as it begins to migrate caudally around E9-E10.  
In the brain, Nkx2.1 transcripts are first detectable in the medial part of the 
proencephalic neural plate as early as the 3-somite stage, and by E10.5 transcripts are 
seen in the progenitor rostroventral diencephalon and telencephalon. Nkx2.1 RNA and 
protein is expressed in both neuroepithelial progenitors and their post-mitotic neurons. By 
E14.5, Nkx2.1 is detectable in many areas of the hypothalamus and telencephalon, an 
expression pattern that persists postnatally (Pan et al. 2004).  
Prenatally, Nkx2.1 expression occurs within the preoptic region and the medial 
ganglionic eminence (MGE) as early as E10.5. These brain areas are thought to give rise 
to the globus pallidus, subclasses of interneurons of the striatum and cortex and 
cholinergic projection neurons of the nucleus basalis (Xu et al. 2008). The MGE also 
gives rise to interneurons in the hippocampal region of the cortex, and postnatally, there 
are numerous Nkx2.1 expressing cells seen scattered throughout the hippocampus.  
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Postnatally, the medial amygdala, which is primarily pallial in origin, displays 
Nkx2.1 expression (Xu et al. 2008). The olfactory bulb also displays Nkx2.1 expression in 
the glomerular layer of the main bulb and in the anterior olfactory nucleus. Nkx2.1 
lineage cells are also found throughout the subcortical telencephalon. Nkx2.1 expression 
is found in nearly all cholinergic projection neurons of the basal telencephalic nuclei that 
also express ChAT. A large number of interneurons of the striatum also express Nkx2.1, 
which is consistent with their origin in the MGE. Expression is also found in the islands 
of Calleja, the diagonal band of Broca, the lateral septal nuclei and the globus pallidus 
(Xu et al. 2008).  
The importance of Nkx2.1 in development of the lungs, thyroid and brain can be 
shown by the Nkx2.1
-/-
 mice. Without the activity of Nkx2.1, the primordium of the lung 
is dysmorphic, leading to perinatal death. The thyroid perimordium is formed in these 
mutants, but it undergoes apoptosis and is eliminated. In the telencephalon, there is a loss 
of structures such as the globus pallidus and striatum expansion. The hypothalamus also 
displays an abnormal morphology and molecular defects (Pan et al. 2004).  
 
5. My Research: Characterization of transgenic expression of 
human 82-kDa ChAT in mouse 
 
Rationale 
 
The functional role of the 82-kDa variant of ChAT is not well established, but 
recent research in our laboratory shows that the presence of 82-kDa ChAT in the nucleus 
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can alter expression of several genes. Thus, in neurons expressing 82-kDa ChAT, there is 
a reduction in the activity and levels of proteins that are involved in amyloidogenic 
processing of APP, with this resulting in decreased Aβ release (Albers et al. 2014). To 
our knowledge, all research on the potential functions of 82-kDa ChAT has been 
conducted in vitro. Therefore, it is necessary to move these studies to an in vivo model. 
As non-primate species do not express 82-kDa ChAT, this provides the option to express 
the protein transgenically in mice to assess its function. To this end, mice expressing 
human 82-kDa ChAT were developed in our laboratory to provide a better understanding 
of the role of this cholinergic protein, and its potential role in function and dysfunction of 
cholinergic neurons. Characterization of the mice expressing human 82-kDa ChAT 
protein is necessary before further experiments with these mice can be performed, and 
forms the basis for my thesis. 
 
Hypothesis 
 
Expression of human 82-kDa ChAT from the pcCALL2:82-ChAT derived 
sequence is dependent on Cre recombinase mediated excision of the floxed LacZ gene.  
 
Objectives  
 
The main objective of my research is to provide better understanding of human 82-
kDa ChAT expression in the transgenic (Tg) 82-kDa hChAT;Nkx2.1-Cre mouse model 
through characterization. A number of sub-objectives were identified to facilitate 
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progress toward the main objective of characterizing the Tg 82-kDa hChAT;Nkx2.1-Cre 
mouse phenotype.  
1. To examine the pcCALL2 and pcCALL2:82-ChAT DNA constructs in HEK 293 
cells by determining ChAT and LacZ protein expression, as well as analyzing 
DNA with PCR primers specific to the pcCALL2 sequences. 
2. To examine the Tg 82-kDa hChAT;Nkx2.1-Cre mouse brain genomic DNA 
utilizing PCR primers specific to hChAT, Cre, LacZ and others found within the 
pcCALL2 sequence and determine how genomic DNA may differ in cortex, 
striatum and basal forebrain. 
3. To determine where in the brain the Tg 82-kDa hChAT;Nkx2.1-Cre mouse 
expresses human 82-kDa ChAT.  
  
23 
 
 
CHAPTER 2: MATERIALS AND METHODS  
 
Materials: 
 
Wild-type (WT) (C57BL/6) mice were purchased from Jackson Laboratory (Bar 
Harbor, ME, USA). Nkx2.1-Cre (C57BL/6J-Tg(Nkx2-1-cre)2Sand/J) mice and the 
pcCALL2 vector were gifts from Dr. Vania Prado (Robarts Research Institute, Western 
University, London, ON). All primers used for PCR, DNAse1, 1 kb DNA ladder and 
Proteinase K were purchased from Invitrogen (Burlington, ON, Canada). Protease 
inhibitor cocktail [4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF)], 
DAPI and REDExtract-N-Amp Tissue PCR Kit were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Qiagen (Venlo, Netherlands) supplied the Taq DNA polymerase kit. 
RedSafe nucleic acid stain was provided by INtRON (San Diego, CA, USA). Genedirex 
(North York, ON) supplied a 1 kb DNA ladder. Protein assay reagent dye, Precision Plus 
protein standards, polyvinylidene difluoride (PVDF) membrane and Clarity Western ECL 
substrate were purchased from BioRad (Hercules, CA, USA). Human carboxyl-terminal 
(CTab) and amino-terminal (NTab) ChAT antibodies were raised in rabbits by GeneMed 
Synthesis (San Antonio, Texas, USA) and immunoglobins were purified in our laboratory 
by affinity chromatography using the antigenic peptides. The antigenic peptide for CTab 
was CEKATRPSQGHQP and recognizes an epitope at the carboxyl-terminus of both 69-
kDa and 82-kDa ChAT and does not cross-react with mouse ChAT. The antigenic 
peptide for NTab was CAEAAEPRRAGPH and recognizes an epitope in the amino-
terminus of human 82-kDa ChAT and does not correspond to any other human or mouse 
proteins when analyzed by BLAST search. Peroxidase-conjugated affinity purified goat 
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anti-rabbit secondary antibody was purchased from Jackson Laboratories (West Grove, 
PA, USA). Bovine serum albumin (BSA) was provided by Calbiochem (Darmstadt, 
Germany). Normal goat serum was purchased from CedarLane Laboratories (Burlington, 
ON, Canada). AlexaFluor 555 donkey anti-rabbit and AlexaFluor 488 goat anti-rabbit 
secondary antibodies were purchased from Invitrogen (Burlington, ON, Canada). Actin 
(I-19)-R antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). Thermo Scientific provided the immunofluorescence mounting media (Carlsbad, 
CA, USA). Microscope coverslips were from Fisher Scientific (Hampton, NH, USA). 
LacZ tissue staining kit was purchased from InvivoGen (San Diego, CA, USA). HEK 293 
cells were purchased from American Type Culture Collection (Manassas, VA, USA). 
Lipofectamine 2000 transfection reagent, Ultrapure Phenol:Chloroform:Isoamyl alcohol, 
fetal bovine serum (FBS), culture media and reagents were purchased from Invitrogen 
(Burlington, ON, Canada). The Amaxa Cell Line Nucleofector Kit V was provided by the 
Lonza Group (Basel, Switzerland).  
 
Cell-based Studies 
 
Culture and Treatment of Cells 
 
HEK 293 cells were grown and maintained in Minimal Essential Media (MEM) 
containing 10% FBS and 10 µg/ml gentamicin. Cells were transiently transfected using 
Lipofectamine 2000 to express either human 69-kDa ChAT (pcDNA3.1 vector), human 
82-kDa ChAT (pcDNA3.1 vector) or empty vector (pcDNA3.1) to use as controls in a 
variety of experiments.  
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A unique DNA construct was developed using a pcCALL2-IRES-GFP 
(pcCALL2) vector and the full-length cDNA encoding human 82-kDa ChAT. The 
pcCALL2 vector contains a LacZ gene flanked by similarly oriented loxP sites, followed 
by an internal ribosomal entry site (IRES) and enhanced green fluorescent protein (GFP) 
gene outside of the floxed sequence. The pcCALL2 vector utilizes a CMV enhancer 
coupled with a chicken β-actin promoter. Figure 3 shows a schematic of the pcCALL2 
vector.  
 
 
Figure 3. pcCALL2-IRES-GFP schematic. pcCALL2 expression of LacZ is driven by 
CMV enhancer and chicken β-actin promoter. The LacZ gene is floxed and is followed 
by a second reporter gene, GFP.  
 
It was determined that the cDNA encoding the human 82-kDa ChAT sequence 
does not contain either AscI or SbfI endonuclease site sequences, and therefore these 
were chosen as sites to allow ligation of the gene of interest into the pcCALL2 vector. 
These restriction sites were added to the 5’ and 3’ ends of the human 82-kDa ChAT 
sequence by PCR, along with a mini Kozak sequence between the 5’ AscI sequence and 
the translation initiation site of 82-kDa ChAT. Following digestion of the PCR product 
with AscI and SbfI, it was ligated to the pcCALL2 vector resulting in creation of the 
plasmid pcCALL2:82-ChAT. This 82-kDa ChAT sequence is between the floxed LacZ 
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gene and the IRES and GFP sequences. Figure 4 shows the insertion of 82-kDa ChAT 
into the pcCALL2 vector (A) and the resulting pcCALL2:82-ChAT plasmid (B). 
 
 
Figure 4. Insertion of human 82-kDa ChAT into the pcCALL2 sequence (A) and the 
resulting pcCALL2:82-ChAT sequence (B). Human 82-kDa ChAT does not contain 
the sequences for AscI and SbfI restriction sites so these sequences were added to the 
ends of the ChAT sequence using PCR. Through restriction enzyme digestion and 
ligation, human 82-kDa ChAT was ligated into the original pcCALL2 sequence. This 
results in a sequence with the original floxed LacZ gene followed by the human 82-kDa 
ChAT sequence and ends with the IRES and GFP sequences. 
 
Transfection or co-transfection of cells with the pcCALL2 vector or pcCALL2: 
82-ChAT plasmid was performed using the Amaxa Cell Line Nucleofector Kit V 
according to the manufacturer’s protocol. All transfections were performed using 
approximately 1.8 x 10
6
 cells/mL on 100 mm dishes using a total of 5 µg of DNA. Cells 
were allowed to express the proteins for 48 h before being collected for assays.  
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Extraction and Analysis of Cellular DNA 
 
To assess whether Cre-mediated excision of the floxed LacZ gene from the 
pcCALL2 derived sequences occurs in the cultured cells, cellular DNA was examined by 
PCR using a variety of primers specific to the pcCALL2 sequences. HEK 293 cells were 
transfected with either pcCALL2 or pcCALL2:82-ChAT, either with or without Cre. A 
separate set of cells were also transfected with the empty vector, pcDNA3.1, to use as a 
negative control. Cells were scraped from the culture dishes into medium and recovered 
by centrifugation (1,000 g for 5 min, at room temperature) then cell pellets were 
resuspended in 500 µL of DNA lysis buffer (100 mM Tris, 5 mM EDTA, 10% SDS, 100 
mM NaCl) containing 10 µL Proteinase K. Cell lysates were incubated in this solution at 
55°C overnight, then 500 µL of Phenol:Chloroform:Isoamyl alcohol was added to cell 
lysate, mixed and centrifuged at 13,000 g for 10 min, at room temperature. The DNA-
containing upper aqueous solution was recovered and 500 µL of isopropyl alcohol was 
added then centrifuged at 10,000 g for 10 min, at 4°C. The resulting DNA pellet was 
washed in 1 mL of 70% ethanol, and re-centrifuged at 10,000 g for 5 min at 4°C. The 
DNA pellets were then dried and solubilised in 40 µL of Tris Ethylenediamine (TE) 
buffer (10 mM Tris, 1mM EDTA). DNA content of each sample was quantified using a 
NanoDrop (Thermo Scientific).  
DNA recovered from the cells was amplified by PCR using sets of primers in 
Table 1. DNA samples being analyzed using the primer sets for ChAT, Cre or chicken β-
actin/ChAT used the Taq DNA polymerase kit (Qiagen) using 200 ng of DNA, whereas 
DNA samples being analyzed using the primer sets for chicken β-actin/LacZ, LacZ, IRES 
or GFP used the RedExtract-N-Amp Tissue PCR Kit from Sigma using 200 ng of DNA. 
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Following the PCR reaction, samples were prepared for agarose gel electrophoresis and 
amplicons were separated on 2% agarose gels containing RedSafe, then DNA was 
visualized using a BioRad ChemiDoc MP Imaging System.  
Table 1. Primer sets used for PCR-based analysis of DNA extracted from HEK 293 
cells transfected with either pcCALL2 or pcCALL2:82-ChAT, with and without the 
presence of Cre. 
Target and 
concentration 
Primer Sets Amplicon 
Size 
ChAT (100 µM) Forward: TGGTTTGTCCAAACTCATCAA 
Reverse: TCCTCCCTCCTCTCTCTTCC 
199 bp 
Chicken β-
actin/ChAT 
(100 µM) 
Forward: GGGCAACGTGCTGGTTATTG 
Reverse: GCAGGGCTGGAGTTGACAGGCAGG 
5710 bp  
(-Cre) 
772 bp (+Cre) 
Chicken β-
actin/LacZ 
(10 µM) 
Forward: GGGCAACGTGCTGGTTATTG 
Reverse: CGTGGCCTGATTCATTCC 
1516 bp 
Cre (5 µM) Forward: GTCCAATTTACTGACCGTACACC 
Reverse: GTTATTCGGATCATCAGCTACACC 
650 bp 
 
GAPDH (5 µM) Forward: TGTTGCCATCAATGACCCCTT 
Reverse: CTCCACGACGTACTCAGCG 
200 bp 
 
GFP (10 µM) 
 
Forward: GTGCTTCAGCCGCTACCCCG 
Reverse: ACCTCGGCGCGGGTCTTGTA 
129 bp 
IRES (10 µM) Forward: CCTTTGCAGGCAGCGGAACC 
Reverse: GCACCGAGGCCCCAGATCAGA 
146 bp 
LacZ (10µM) Forward: ATCCTCTGCATGGTCAGGTC 
Reverse: CGTGGCCTGATTCATTCC 
300 bp 
 
LacZ Staining of Cells 
 
To further assess whether Cre-mediated excision of the floxed LacZ gene from 
the pcCALL2-derived sequences occurs in the cultured cells, cells were stained for β-
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galactosidase to determine if they expressed the LacZ gene. HEK 293 cells were 
transfected with plasmids encoding either human 69-kDa ChAT or human 82-kDa ChAT, 
or with either the pcCALL2 vector or the pcCALL2:82-ChAT plasmid with and without 
Cre. Cells were plated onto 35 mm cell culture plates, then grown for 48 h before being 
fixed and subjected to LacZ staining using the LacZ Tissue Staining Kit, according to 
manufacturer’s instructions. Cell staining was imaged on an Olympus BX45 light 
microscope.  
 
Immunofluorescence Staining of Cells 
 
Transfected cells were plated onto glass coverslips at a density of approximately  
3 x 10
5
 cells/mL. After 48 h, cells were fixed with 4% formaldehyde for 30 min at 4°C 
then permeabilized for 5 min at room temperature using 0.5% Triton X-100 in PBS. Non-
specific binding sites were blocked by incubating coverslips with 3% normal goat serum 
in PBS (3%GS-PBS) for 30 min at room temperature. Coverslips were then incubated 
with CTab primary antibody at a concentration of 1:1,000 in 3%GS-PBS. Following 
washing, coverslips were incubated with an AlexaFluor 555-conjugated donkey anti-
rabbit secondary antibody at a concentration of 1:1,000 in 3%GS-PBS for 1 h at room 
temperature. Coverslips were mounted on slides using Immunomount and 
immunopositive cells visualized using a Zeiss Axiovert 200 microscope. 
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Immunoblots on Cell Lysates 
 
To access the expression of human 82-kDa ChAT protein in cells transiently 
transfected with various plasmids, cells were lysed using RIPA buffer (10 mM Tris HCl 
pH 7.5; 140 mM NaCl; 1% v/v Triton X-100; 1% w/v sodium deoxycholate; 0.1% 
sodium dodecyl sulfate) containing 800 Units/mL of DNAseI and 10 µL/mL of protease 
inhibitor cocktail at 48 h following transfection. The protein concentration was measured 
by Bradford assay using BioRad protein assay reagent dye.  
Aliquots of cell lysates containing either 10 µg of protein [cells transfected with 
either 69-kDa ChAT-pcDNA3.1 and 82-kDa ChAT-pcDNA3.1] or 100 µg of protein 
[cells transfected with either pcCALL2, pcCALL2:82-ChAT, pcCALL2 + Cre or 
pcCALL2:82-ChAT + Cre] were separated by electrophoresis on a 7.5% SDS-PAGE gel. 
Proteins were transferred to PVDF membranes using the BioRad Transblot Turbo 
transfer system for 20 min (constant A: 2.5 A, 25 V limit). Membranes were incubated 
with 8% non-fat dried milk in PBS containing 0.15% Triton X-100 (PBST) for 1 h at 
room temperature to block non-specific sites. Membranes were then incubated with a 
primary antibody specific for the C-terminus of human ChAT (CTab at 1:1,000) 
overnight at 4°C in 8% milk in PBS-T. Subsequently, membranes were washed and 
incubated with secondary antibody (peroxidase-conjugated affinity purified goat anti-
rabbit at 1:10,000) in 8% milk in PBS-T for 1 h at room temperature. Immunoreactive 
proteins were detected with Clarity Western ECL substrate on a BioRad Chemidoc MP 
imaging system. Blotting membranes were stripped (62.5 mM Tris-HCl pH 6.7, 2% SDS, 
0.78% 2-mercaptoethanol), then washed, blocked and reprobed with a primary antibody 
recognizing an epitope in the amino-terminus of human 82-kDa ChAT (NTab, 1:200) to 
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reconfirm the identity of this protein. The same secondary antibody and concentration 
was used as above to facilitate visualization of immunoreactive proteins. Blots were also 
probed for β-actin (primary antibody 1:1,000; secondary antibody: 1:10,000) as a loading 
control. 
 
In Vivo Studies 
 
Development of Transgenic Mice Expressing Human 82-kDa ChAT 
 
The pcCALL2:82-ChAT plasmid was linearized and extraneous DNA sequence 
removed by endonuclease digestion, then the resulting purified DNA was provided to the 
London Regional Gene Targeting and Transgenic Facility for production of founder Tg 
82-kDa hChAT mice (hereafter called 82-hChAT) on a C57BL/6 background. These 
resulting mice are genotypically LacZ+ and ChAT+, but they are expected not to express 
the 82-kDa ChAT protein because of the presence of the floxed LacZ sequence and 
STOP codon between the promoter and the ChAT sequence.  
These 82-hChAT mice were crossed with Nkx2.1-Cre mice (C57BL/6J-Tg(Nkx2-
1-cre)2Sand/J) which express Cre recombinase in cells under the driver of Nkx2.1. The 
resulting offspring expressing both Cre and ChAT are called Tg 82-kDa hChAT;Nkx2.1-
Cre mice (hereafter called 82-hChAT;NkCre). Mediated by Cre recombinase, the floxed 
LacZ gene is excised which is expected to allow expression of human 82-kDa ChAT in 
Nkx2.1 expressing cells. Figure 5 shows the excision of the floxed LacZ gene by Cre 
recombinase (A) and the resulting sequence (B).  
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Figure 5. Excision of LacZ from pcCALL2:82-ChAT by Cre recombinase (A) and 
the resulting sequence (B). Under the control of the Nkx2.1 promoter, Cre recombinase 
mediates the excision of the floxed LacZ gene in the 82-hChAT;NkCre double transgenic 
mice. Prior to LacZ excision, human 82-kDa ChAT is not expressed, however following 
excision the promoter drives 82-kDa ChAT expression. 
 
Breeding and Care of Transgenic Mice 
 
The 82-hChAT founder mice were bred with WT C57BL/6 mice to expand the 
colony. The resulting hemizygous mice are also crossed with hemizygous Nkx2.1-Cre 
mice resulting in 82-hChAT;NkCre offspring that are also crossed with WT mice to 
expand the colony of this strain. Mouse colonies were maintained on a 12-hour light and 
dark schedule with normal mouse chow and water ad libitum, and all procedures were 
approved by the Animal Use Subcommittee (University of Western Ontario) in 
accordance with the guidelines set by the Canadian Council on Animal Care.  
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Genotyping of Mice 
 
Tail samples were obtained from mouse pups on Day 7 for assessment of LacZ 
expression using the LacZ Tissue Staining Kit. Toe samples were also collected from 
mouse pups at Day 7 for genotyping using the Taq DNA polymerase kit from Qiagen. 
For genotyping, tissues were digested using DNA lysis buffer (100mM Tris, 5mM 
EDTA, 10% SDS, 100mM NaCl) containing Proteinase K, then DNA was extracted as 
described above for DNA from cultured cells. PCR amplification was carried out using 
the primer sets listed in Table 2. PCR reactions were loaded onto 1% agarose gels for 
electrophoresis, and then amplicons were visualized using RedSafe nucleic acid stain on 
a BioRad Chemidoc MP imaging system. 
 
Table 2. Primer sets used for genotyping of 82-hChAT and 82-hChAT;NkCre 
transgenic mice 
Target and 
concentration 
Primer Sets Amplicon Size 
ChAT 
(100 µM) 
Forward: TGGTTTGTCCAAACTCATCAA 
Reverse: TCCTCCCTCCTCTCTCTTCC 
199 bp 
Cre (5 µM) Forward: GTCCAATTTACTGACCGTACACC 
Reverse: GTTATTCGGATCATCAGCTACACC 
650 bp 
 
 
Brain Tissue Preparation  
 
WT, 82-hChAT and 82-hChAT;NkCre mice, aged approximately 6 weeks, were 
sacrificed and brains were removed. For the analysis of protein expression in brain tissue 
by immunofluorescence staining and by immunoblotting, brains were bisected along the 
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midline, with the right half of the brain processed for histology and the left half of the 
brain frozen in liquid nitrogen then stored at -80°C for later use in immunoblots. 
Brain halves were fixed by immersion fixation of the tissues in 4% formaldehyde 
for 24 h, followed by immersion in a 30% sucrose solution for 24 h before being paraffin 
embedded. Coronal brain sections were cut at 5 µm thickness.  
To prepare samples for analysis by immunoblotting, frozen brain halves, minus 
the cerebellum were cut coronally into 4 parts: the front of the brain containing 
predominantly cortex, a middle front section containing the basal forebrain, cortex and 
striatum, a middle back section containing cortex, striatum, and hippocampus, and a back 
section containing hippocampus and cortex. Tissue samples were placed in RIPA buffer 
(10 mM Tris HCl pH 7.5; 140 mM NaCl; 1% Triton X-100; 1% sodium deoxycholate; 
0.1% sodium dodecyl sulfate) containing 800 Units/mL of DNAseI and 10 µL/mL of 
protease inhibitor cocktail then disrupted by sonication with a Sonic Dismembrator 
Model 100 (Fisher Scientific, Hampton, NH, USA). Samples were solubilized by gentle 
mixing on a rotator at 4°C for 1 h, and then centrifuged at 15,000 g for 15 min at 4°C. 
The resulting supernatants were retained and the pellets were discarded. The protein 
concentration of the supernatants was determined using a Bradford assay with BioRad 
protein assay reagent dye.  
 
Immunofluorescence Staining of Brain Tissues 
 
Paraffin-embedded brain sections were de-paraffinized with xylene, then 
rehydrated through ethanol diluted in water at the following concentrations: 100% 
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ethanol, 95% ethanol, 70% ethanol, 50% ethanol, water. Brain sections were subjected to 
antigen retrieval (10 mM sodium citrate in a pressure cooker) before being incubated in 
PBS-0.25% Triton X-100 for 10 min. Non-specific binding was blocked with 5% BSA in 
PBS containing 0.3% Triton X-100 for 1 h at room temperature, then sections were 
washed in PBS. Sections were then incubated overnight at 4°C in CTab primary antibody 
(1:1,000) in 5% BSA in PBS containing 0.1% Triton X-100. Sections were washed in 
PBS, then incubated in AlexaFluor 488-conjugated goat anti-rabbit secondary antibody 
(1:1,000) in 5% BSA, 0.1% Triton X-100 for 1 h at room temperature. Following 
washing, sections were counter-stained with DAPI, cover-slipped with Immunomount 
and imaged on a Zeiss Axiovert 200M microscope. Images were analyzed using 
Axiovision 4.8 software. Three separate mouse brains for both 82-hChAT and 82-
hChAT;NkCre mice were analyzed by immunofluorescence staining. 
 
Immunoblots on Brain Tissue 
 
To determine if human 82-kDa ChAT protein could be detected in 82-
hChAT;NkCre mice, aliquots of brain lysate containing 100 µg of protein were treated 
with 3x Laemmli buffer then separated on 7.5% SDS-PAGE gels. Proteins were 
transferred from the gels to PVDF membranes using the BioRad Transblot Turbo transfer 
system for 20 min (constant A: 2.5 A, 25 V limit). Non-specific binding sites on 
membranes were blocked with 8% non-fat dried milk in PBS containing 0.15% Triton X-
100 (PBS-T) for 1 h at room temperature. Membranes were then incubated with a 
primary antibody specific for the carboxyl-terminal of human ChAT (CTab, 1:1,000) in 
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8% milk in PBS-T overnight at 4°C. Subsequently, membranes were washed and 
incubated with peroxidase-conjugated affinity-purified goat anti-rabbit secondary 
antibody (1:10,000) in 8% milk in PBS-T for 1 h at room temperature. Following 
washing of the membranes, immunopositive proteins were detected with Clarity Western 
ECL substrate on a BioRad Chemidoc MP imaging system. 
 
Analysis of Mouse Brain Genomic DNA 
 
Additional WT, 82-hChAT and 82-hChAT;NkCre mice were sacrificed and the 
brains removed for the analysis of genomic DNA. Fresh brains were rapidly dissected 
into cortex, striatum and basal forebrain, then frozen in liquid nitrogen and stored until 
assay at -80°C. Frozen tissue samples were placed in DNA lysis buffer containing 
Proteinase K and genomic DNA was extracted in the same manner as described above for 
cellular DNA and genomic DNA preparation for genotyping.  
The concentration of genomic DNA in each sample was quantified using a 
Nanodrop, and then aliquots containing 200 ng DNA were amplified by PCR using the 
primer sets given in Table 3. The internal primers are specific to C57BL/6 mice and are 
located on chromosome 5. Samples being amplified for chicken β-actin/ChAT, ChAT, 
and Cre utilized the Taq DNA Polymerase Kit (Qiagen), whereas samples amplified for 
chicken β-actin/LacZ, LacZ, IRES, or GFP used the RedExtract-N-Amp Tissue PCR Kit 
(Sigma). PCR reactions were electrophoresed on 2% agarose gels with RedSafe then 
amplification products were visualized using a BioRad ChemiDoc MP Imaging System. 
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Table 3: Primer sets used for PCR based analysis of genomic DNA extracted from 
cortex, striatum and basal forebrain of wild-type, 82-hChAT and 82-hChAT;NkCre 
brains 
Target and 
Concentration 
Primer Sets Amplicon 
Size 
ChAT (100 µM) Forward: TGGTTTGTCCAAACTCATCAA 
Reverse: TCCTCCCTCCTCTCTCTTCC 
199 bp 
Chicken β-
actin/ChAT (100 µM) 
Forward: GGGCAACGTGCTGGTTATTG 
Reverse: 
GCAGGGCTGGAGTTGACAGGCAGG 
5710 bp  
(-Cre) 
772 bp 
(+Cre) 
Chicken β-actin/LacZ 
(10 µM) 
Forward: GGGCAACGTGCTGGTTATTG 
Reverse: CGTGGCCTGATTCATTCC 
1516 bp 
Cre (5 µM) Forward: GTCCAATTTACTGACCGTACACC 
Reverse: GTTATTCGGATCATCAGCTACACC 
650 bp 
 
GFP (10 µM) 
 
Forward: GTGCTTCAGCCGCTACCCCG 
Reverse: ACCTCGGCGCGGGTCTTGTA 
129 bp 
Internal Primer-89 (10 
µM) 
Forward: GCAAGCCTGGGGTTTTCTTG 
Reverse: CCTTCTGACCCATTCCCACC 
89 bp 
Internal Primer-223 
(10 µM) 
Forward: CTTAGCTTGGTGAGGGTGGG 
Reverse: CGGACTCATCGTACTCCTGC 
223 bp 
IRES (10 µM) Forward: CCTTTGCAGGCAGCGGAACC 
Reverse: GCACCGAGGCCCCAGATCAGA 
146 bp 
 
LacZ (10 µM) Forward: ATCCTCTGCATGGTCAGGTC 
Reverse: CGTGGCCTGATTCATTCC 
300 bp 
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CHAPTER 3: RESULTS 
 
1. Cell-based Studies 
 
The goal of the cell-based experiments in my thesis was to provide a model to 
examine expression of the DNA construct that was used for the creation of the human 82-
kDa ChAT-expressing transgenic mouse in the presence and absence of Cre recombinase 
expression. The experimental model used was transiently transfected HEK 293 cells. 
Two separate methods were used to transfect cells depending on the size of the DNA 
plasmids to be expressed. For smaller plasmids with sizes fewer than 10 kb, such as the 
human 69-kDa ChAT or 82-kDa ChAT ligated into pcDNA3.1 or the empty vector 
pcDNA3.1, Lipofectamine 2000 was used to introduce DNA into the cells. For larger 
plasmids with sizes greater than 10 kb, cells were transfected using nucleofection. This 
was used with the pcCALL2 vector or pcCALL2:82-ChAT plasmid, or for co-
transfection of these plasmids with the Cre-expressing plasmid pcAGGS-nls Cre. Cells 
were cultured for 48 h following transfection to allow protein expression before being 
used in experiments.  
 
Examination of DNA extracted from transfected cells 
 
To document the presence of gene elements specific to the pcCALL2 vector 
backbone, I examined DNA extracted from cells transfected with the pcCALL2 vector 
and the pcCALL2:82-ChAT plasmid by PCR. One critical question relates to the 
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conditions under which 82-kDa ChAT is expressed in the cells, and if this requires the 
co-expression of a plasmid that promotes the expression of Cre recombinase. At 48 h 
after transfection, DNA was evaluated by PCR using the primer sets listed in Table 1 in 
Chapter 2.  
As seen in Figures 6, 7 and 8 all pcCALL2 vector transfected cell groups are 
positive for LacZ, IRES and GFP sequences with the PCR reactions revealing amplicons 
of the appropriate sizes based on the primers used of 300 bp, 146 bp, and 129 bp 
respectively. Cells transfected with the pcCALL2:82-ChAT plasmid either in the 
presence or the absence of Cre expressing plasmid also yielded an amplicon of 199 bp 
that was appropriate based on the hChAT primers used (Figure 9). Cells co-transfected 
with the pcAGGS-nls Cre plasmid yielded a Cre-specific amplicon of 650 bp (Figure 10).  
Next, I evaluated the Cre-mediated excision of the floxed LacZ gene and 
conditions that could result in the expression of 82-kDa ChAT in cells using the 
pcCALL2:82-ChAT and Cre-expressing plasmids. PCR primer sets were designed that 
either crossed the LoxP site between the chicken β-actin promoter and the LacZ gene in 
the pcCALL2:82-ChAT plasmid (Actin/LacZ), or that spanned the floxed LacZ gene with 
the forward primer in the chicken β-actin promoter sequence and the reverse primer in the 
hChAT sequence (Actin/ChAT). As shown in Figure 11, PCR analysis of DNA from 
cells transfected with either pcCALL2 or pcCALL2:82-ChAT yielded a PCR amplicon 
with a size of approximately 1516 bp for Actin/LacZ, while those co-transfected with Cre 
yielded a band of the same size, but with a decrease in the amplicon band intensity. A 
critical finding shown in Figure 12 is that only cells co-transfected with the 
pcCALL2:82-ChAT plasmid in combination with the Cre-expressing plasmid resulted in 
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the production of a PCR amplicon of 772 bp that would be created with the Actin/ChAT 
primer set if Cre had excised the floxed LacZ gene. Thus, DNA obtained from cells 
transfected with the pcCALL2 vector either with and without the Cre-expressing plasmid 
did not yield this PCR amplicon for the Actin/ChAT primer set, nor did DNA from cells 
transfected with the pcCALL2:82-ChAT plasmid in the absence of the Cre-expressing 
plasmid. I predicted that PCR-based analysis of the DNA prepared from cells expressing 
pcCALL2:82-ChAT plasmid in absence of the Cre-expressing plasmid using the 
Actin/ChAT primer set would result in the production of a much larger amplicon of 5710 
bp. This amplicon was not observed, likely due to the PCR conditions not being 
favourable for the production of such a large DNA product. PCR analysis obtained from 
cells transfected with the empty vector as a negative control did not result in the 
production of an amplicon with any of the primer sets tested in these experiments. DNA 
prepared from all of the sets of transfected cells showed PCR amplification products for 
GAPDH, which was used as an internal positive control (Figure 13).  
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Figure 6. All pcCALL2 vector-based plasmids encode the LacZ gene both in the 
presence and the absence of expression of the Cre-expressing plasmid. Panel A 
shows that an amplicon of 300 bp size was detected that is consistent with the LacZ 
primers used in all cell groups transfected with either the pcCALL2 vector or the 
pcCALL2:82-ChAT plasmid, and either with or without the presence of the Cre-
expressing plasmid. Cells transfected with the empty vector pcDNA3.1 did not display 
this LacZ amplicon (n=3). Panel B illustrates schematically the approximate location of 
the forward (F) and reverse (R) primers for PCR-based amplification of a portion of the 
LacZ sequence on the pcCALL2:82-ChAT plasmid.  
  
42 
 
 
 
 
 
Figure 7. All pcCALL2 vector-based plasmids encode the IRES gene both in the 
presence and the absence of expression of the Cre-expressing plasmid. Panel A 
shows that an amplicon of 146 bp size was detected that is consistent with the IRES 
primers used in all cell groups transfected with either the PCCALL2 vector or the 
pcCALL2:82-ChAT plasmid, and either with or without the presence of the Cre-
expressing plasmid. Cells transfected with the empty vector pcDNA3.1 did not display 
this IRES amplicon (n=3). Panel B illustrates schematically the approximate location of 
the forward (F) and reverse (R) primers for PCR-based amplification of a portion of the 
IRES sequence on the pcCALL2:82-ChAT plasmid.  
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Figure 8. All pcCALL2 vector-based plasmids encode the GFP gene both in the 
presence and the absence of expression of the Cre-expressing plasmid. Panel A 
shows that an amplicon of 129 bp size was detected that is consistent with the GFP 
primers used in all cell groups transfected with either the pcCALL2 vector or the 
pcCALL2:82-ChAT plasmid, and either with or without the presence of the Cre-
expressing plasmid. Cells transfected with the empty vector pcDNA3.1 did not display 
this GFP amplicon (n=3). Panel B illustrates schematically the approximate location of 
the forward (F) and reverse (R) primers for PCR-based amplification of a portion of the 
GFP sequence on the pcCALL2:82-ChAT plasmid.  
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Figure 9. The pcCALL2:82-ChAT plasmid contains the human 82-kDa ChAT gene 
in the presence and the absence of the Cre-expressing plasmid. Panel A shows that an 
amplicon of 199 bp size was detected that is consistent with the hChAT primers used in 
the cell groups that were transfected with the pcCALL2:82-ChAT plasmid in either the 
absence or the presence of the Cre-expressing plasmid. Cells transfected with pcCALL2 
vector in either presence or absence of Cre-expressing plasmid, or the empty vector 
pcDNA3.1 do not display this hChAT amplicon (n=3). Panel B illustrates schematically 
the approximate location of the forward (F) and reverse (R) primers for PCR-based 
amplification of a portion of the hChAT sequence on the pcCALL2:82-ChAT plasmid. 
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Figure 10. Only cells transfected with the Cre-expressing plasmid contain the Cre 
gene. Panel A shows that an amplicon of 650 bp size was detected that is consistent with 
the Cre primers used in the cell groups that were transfected with Cre-expressing plasmid 
in the presence of either the pcCALL2 vector or the pcCALL2:82-ChAT plasmid. Cells 
transfected with the empty vector pcDNA3.1 do not display this Cre amplicon (n=3). 
Panel B illustrates schematically the location at which Cre recombinase mediates 
excision of the LacZ gene.   
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Figure 11. Cells transfected with either pcCALL2 or pcCALL2:82-ChAT in either 
the presence or the absence of the Cre-expressing plasmid display the Actin/LacZ 
amplicon. Panel A shows that an amplicon of 1516 bp size was detected that is 
consistent with the Actin/LacZ primer set used in the cell groups that were transfected 
with the pcCALL2 vector or pcCALL2:82-ChAT plasmid, either in the presence or the 
absence of the Cre-expressing plasmid. Cells transfected with the empty vector 
pcDNA3.1 do not display this amplicon (n=3). The amplicon intensity appears to be 
decreased in those cells co-transfected with the Cre-expressing plasmid. Panel B 
illustrates schematically the approximate location of the forward (F) and reverse (R) 
primers for PCR-based amplification of a portion of the sequence that crosses the LoxP 
site between the chicken -actin promoter and the LacZ gene on the pcCALL2:82-ChAT 
plasmid.  
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Figure 12. Floxed LacZ is excised from the plasmid DNA in cells co-transfected with 
the pcCALL2:82-ChAT and Cre-expressing plasmids. Panel A shows that an 
amplicon of 772 bp size was detected that is consistent with the Actin/ChAT primers 
used only in the cells that were co-transfected with the pcCALL2:82-ChAT plasmid and 
the Cre-expressing plasmid. A larger amplicon of approximately 5710 bp is predicted in 
cells transfected with only the pcCALL2:82-ChAT plasmid, but this was not observed. 
Cells transfected with the pcCALL2 vector in either the absence or the presence of the 
Cre-expressing plasmid, or with the empty vector pcDNA3.1 do not display this 
Actin/ChAT amplicon (n=3). Panel B illustrates schematically the approximate locations 
of the forward (F) and reverse (R) primers for PCR-based amplification of a portion of 
the sequence that crosses the two LoxP sites and LacZ gene between the chicken -actin 
promoter and the hChAT gene on the pcCALL2:82-ChAT plasmid.  
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Figure 13. GAPDH was used as an internal positive control for transfected HEK 293 
cells. All transfected cell groups contain an amplicon of 200 bp that is consistent with the 
GAPDH primers. Amplification of this primer set acts as an internal control and shows 
that the DNA extracted from the cells was able to be amplified.  
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Cre recombinase mediates the excision of the floxed LacZ gene 
 
I next determined whether the LacZ reporter gene is expressed in cells transiently 
transfected with either the pcCALL2 vector or the plasmid pcCALL2:82-ChAT, and 
whether the co-expression with the Cre plasmid mediates the excision of the LacZ 
reporter gene. HEK 293 cells were transiently transfected with plasmids encoding either 
human 69-kDa ChAT or 82-kDa ChAT in pcDNA3.1 as control, or with either pcCALL2 
vector or pcCALL2:82-ChAT plasmid with and without the pcAGGS nls Cre plasmid, 
then stained using a LacZ staining kit to assess β-galactosidase (β-gal) activity. Figure 14 
shows that cells transfected to express either human 69-kDa ChAT (Panel A) or human 
82-kDa ChAT (Panel B) do not exhibit blue β-gal staining. By comparison, cells 
transfected with either pcCALL2 vector (Panel C) or the pcCALL2:82-ChAT plasmid 
(Panel D) without the co-expression with the Cre plasmid, exhibit a blue coloured 
staining indicating the expression of β-gal. Importantly, cells that were co-transfected 
with either the pcCALL2 vector (Panel E) or pcCALL2:82-ChAT plasmid (Panel F) in 
conjunction with the pcAGGS nls Cre plasmid have very few blue β-gal-positive cells 
(indicated by arrows). These results suggest that the co-expression of Cre is able to 
mediate the excision of the floxed LacZ gene encoded by the pcCALL2 vector-based 
plasmids. 
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Figure 14. Expression of the LacZ gene is necessary to exhibit β-galactosidase-
positive staining of cells. Cells transfected with plasmids encoding either human 69-kDa 
ChAT (Panel A) or 82-kDa ChAT (Panel B) do not display blue staining as the 
pcDNA3.1 vector does not encode the LacZ gene. Strong blue LacZ staining is present in 
cells transfected with either the pcCALL2 vector (Panel C) or the pcCALL2:82-ChAT 
plasmid (Panel D), compared to the weaker blue LacZ staining in some cells co-
transfected with the Cre-expressing plasmid along with either the pcCALL2 vector 
(Panel E), or the pcCALL2:82-ChAT plasmid (Panel F).The scale bar indicates 10 µm 
while the arrows identify representative cells that contain blue LacZ staining.  
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Cre recombinase-mediated excision of the LacZ gene is necessary for the expression 
of human 82-kDa ChAT 
 
To determine whether the expression of human 82-kDa ChAT from the 
pcCALL2:82-ChAT plasmid is detected following the excision of the floxed LacZ gene 
from the plasmid by Cre recombinase, I analysed transfected cells for human 82-kDa 
ChAT protein expression by both immunoblot and immunofluorescence staining. HEK 
293 cells were transfected with plasmids encoding either human 69-kDa ChAT, or human 
82-kDa ChAT in the pcDNA3.1 vector to be used as positive controls for these two forms 
of ChAT. Separate sets of HEK 293 cells were transfected with either the pcCALL2 
vector or the pcCALL2:82-ChAT plasmid, with or without co-transfection of the 
pcAGGS nls Cre plasmid. As shown in the immunoblot in Figure 15, the expression of 
human 82-kDa ChAT is present only in the lysate from cells co-transfected with the 
pcCALL2:82-ChAT and the Cre-expressing plasmid. The human 82-kDa ChAT protein 
band was observed when the immunoblot was probed with the CTab primary antibody 
that recognizes the carboxyl-terminus of both 69-kDa ChAT and 82-kDa ChAT. The blot 
was stripped and reprobed with the NTab antibody that recognizes an epitope contained 
specifically in the 82-kDa ChAT protein, and this identified the same immunoreactive 
protein band (Figure 15). Cell lysates containing human 69-kDa ChAT and human 82-
kDa ChAT provide positive controls for the CTab and NTab antibodies and to compare 
protein size.  
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Figure 15. Expression of human 82-kDa ChAT is detected in cells co-transfected 
with the pcCALL2:82-ChAT and Cre-expressing plasmids. Aliquots of lysates 
containing 10 µg of protein from cells transfected to express either human 69-kDa ChAT 
or 82-kDa ChAT protein or 100 µg of protein from cells transfected to express either the 
pcCALL2-vector or pcCALL2:82-ChAT plasmid, either with or without the Cre-
expressing plasmid were loaded onto SDS-PAGE gels for electrophoresis. The carboxyl-
terminal antibody (CTab; 1:1,000) recognizes both 69-kDa ChAT and 82-kDa ChAT 
protein, whereas the amino-terminal antibody (NTab; 1:200) identifies only the 82-kDa 
ChAT protein. The 82-kDa ChAT protein is seen only with co-expression of the Cre-
expressing plasmid with the 82-kDa ChAT expressing plasmid. When the immunoblot 
developed with CTab antibody was stripped and re-probed with the NTab antibody, a 
similar result was obtained. The actin immunoblot was used as a control for sample 
protein loading.  
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To further assess the expression of human 82-kDa ChAT in transfected cells, 
immunofluorescence staining was performed with the human ChAT specific antibody, 
CTab. Transfected cells were fixed using 4% paraformaldehyde prior to being stained for 
hChAT protein as illustrated in Figure 16. The pcCALL2 vector also encodes the GFP 
gene, so cells expressing constructs prepared with this vector will express GFP. The 
pcDNA3.1 vector does not contain GFP. As shown in Figure 16, cells transfected with 
the pcCALL2 vector either with or without the Cre-expressing plasmid do not express the 
human 82-kDa ChAT protein. Similarly, cells expressing pcCALL2:82-ChAT in absence 
of the Cre-expressing plasmid also do not express the protein. Importantly, however, 
when co-expressed with the Cre-expressing plasmid, 82-kDa ChAT protein is expressed 
from the pcCALL2:82-ChAT plasmid. This hChAT protein appears to be predominantly 
nuclear in location based on cell morphology, but this would have to be confirmed with 
the co-localization of a nuclear stain such as DAPI counterstain. These results indicate 
that Cre recombinase activity is necessary to mediate expression of human 82-kDa ChAT 
in the cells.  
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Figure 16. Cre recombinase activity is necessary for human 82-kDa ChAT 
expression from pcCALL2 derived sequences. Transfected cells were stained with 
CTab (1:1,000) and visualized on a fluorescence microscope. Cells transfected with 69-
kDa and 82-kDa ChAT display predominantly cytoplasmic and nuclear localization, 
respectively. Cells transfected with pcCALL2, pcCALL2:82-ChAT or pcCALL2 + Cre 
display GFP staining (green) but no hChAT staining (orange). Those cells that are co-
transfected with pcCALL2:82-ChAT and Cre-expressing plasmids display human 82-kDa 
ChAT staining, which seems to have a predominantly nuclear localization. The scale 
represents 20 µm.  
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2. In vivo Studies 
 
The experimental models that were used in the in vivo studies reported in this 
thesis are the 82-hChAT mice and the 82-hChAT;NkCre mice. WT C57BL/6 mice were 
also used in some experiments as a negative control for comparison. These mice allow us 
to test the hypothesis that Cre recombinase activity is necessary for the in vivo expression 
of human 82-kDa ChAT and therefore that the double transgenic 82-hChAT;NkCre mice 
will express human 82-kDa ChAT in areas under the control of the Nkx2.1 promoter.  
 
Genotyping of 82-hChAT and 82-hChAT;NkCre mouse pups 
 
The 82-hChAT founder mice were mated with WT C57BL/6 mice, and tail and 
toe samples were collected from mouse pups to be used for genotyping and LacZ 
staining. Tail samples were subjected to LacZ staining and it was considered that mice 
exhibiting strong blue tail staining indicative of LacZ gene expression should also contain 
the hChAT gene. However, since the hChAT gene would not be expressed in these mice 
due to presence of the floxed LacZ gene, it was not possible to test for hChAT protein 
expression directly. Toe samples were also used for semi-quantitative PCR analysis to 
confirm the presence of the human 82-kDa ChAT transgene. The 82-hChAT mouse line 
is maintained by continual crossing of positive offspring with WT mice. Figure 17 shows 
representative PCR genotyping results using primers specific to hChAT from one litter 
and representative tail samples that show both positive and negative tail for LacZ 
staining. In this litter, mice numbered 1, 2, 3, 7 and 8 indicate positive ChAT genotyping.   
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Figure 17. Genotyping results from a representative litter following the mating of 
82-hChAT mouse with a WT. Tail and toe samples were collected from mouse pups on 
postnatal day 7. Tail samples were subjected to LacZ staining and toe samples were 
processed for genotyping by semi-quantitative PCR analysis. Mice were deemed to be 
82-hChAT only if they displayed both ChAT-positive genotyping and LacZ-positive 
staining. In this Figure, mice numbered 1, 2, 3, 7 and 8 display bands corresponding to 
hChAT, but only mice numbered 1, 2 and 7 were LacZ-positive (not shown) and 
therefore considered to be 82-hChAT. The tail LacZ staining image shows representative 
tail samples from LacZ-negative (A) and LacZ-positive (B) staining. Blue tail staining 
indicates positive LacZ staining.  
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Following genotyping, mice that were found to have both ChAT-positive 
genotyping and LacZ-positive tail staining were deemed to be 82-hChAT mice, and were 
used in subsequent studies.  
The 82-hChAT mice were used as a control in a variety of studies in this thesis 
and were crossed with the Nkx2.1-Cre mice. Mouse pup toe samples were taken at 
postnatal day 7 and subjected to semi-quantitative PCR analysis with primer sets for Cre 
and hChAT. Figure 18 shows the results of Cre and hChAT genotyping for a 
representative litter and demonstrates that mice numbered 2, 3, 4, 5, 6, and 8 are deemed 
to be 82-hChAT;NkCre mice. Mice numbered 1 and 9 are Cre-negative/ChAT-positive, 
mouse 2 is Cre-positive/ChAT-negative and mouse 7 is negative for both Cre and ChAT 
upon genotyping.  
Mouse pups that were determined to be both Cre-positive and hChAT-positive 
were called 82-hChAT;NkCre mice and were used in subsequent experiments to 
characterize the expression of human 82-kDa ChAT in the double transgenic mice.  
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Figure 18. Genotyping of a litter following mating of an 82-hChAT mouse with an 
Nkx2.1-Cre mouse. Toe samples were collected on postnatal day 7 and processed for 
semi-quantitative PCR analysis. Mice were deemed to be 82-hChAT;NkCre if they 
displayed both ChAT-positive and Cre-positive genotyping. Mice numbered 3, 4, 5, 6 and 
8 in this litter were found to be 82-hChAT;NkCre mice. Panel A shows the DNA gel 
specific to Cre primers, while Panel B shows the DNA gel with primers specific to 
hChAT. 
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Examination of genomic DNA prepared from cerebral cortex, striatum and basal 
forebrain from 82-hChAT and 82-hChAT;NkCre mice 
 
To determine the presence of gene elements specific to pcCALL2 vector-based 
plasmids and whether the presence of these gene elements differs in various brain areas, 
genomic DNA was extracted and analyzed using PCR primer sets specific to the 
pcCALL2 and pcCALL2:82-ChAT sequences. WT (n=3), 82-hChAT (n=3) and 82-
hChAT;NkCre (n=5) mice were sacrificed and their brains dissected into cortex, striatum 
and basal forebrain.  
Figure 19 shows the results of PCR using the hChAT specific primers. Both the 
82-hChAT and 82-hChAT;NkCre mice display an amplicon of correct size (199 bp) 
corresponding to amplification from the hChAT gene sequence from DNA isolated from 
all three brain areas tested. WT mice do not display an amplicon corresponding to the 
hChAT gene.  
Figure 20 shows that only those mice that are 82-hChAT;NkCre display an 
amplicon of 650 bp that corresponds to amplification of a sequence encoded by Cre 
recombinase. The gene corresponding to Cre recombinase is found in all three brain areas 
examined. The 650 bp amplicon is not amplified from DNA prepared from the brain 
tissue from either the WT or 82-hChAT mice.  
Figures 21 and 22 display amplicons corresponding to IRES and GFP (146 bp and 
129 bp respectively) following PCR-based amplification of DNA prepared from the 82-
hChAT and the 82-hChAT;NkCre mice, but not the WT mice. These bands are present in 
all 3 brain areas assessed. Figure 23 illustrates results obtained from PCRs using primers 
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recognizing a sequence within the LacZ gene. It was found that both the 82-hChAT and 
82-hChAT;NkCre mice display an amplicon of 300 bp in all brain areas, whereas WT 
mice do not display this amplicon. It was predicted that there could be a decrease in 
amplicon strength from the basal forebrain DNA samples from 82-hChAT;NkCre mice as 
compared to striatum, and cortex, but this was not observed.  
Figure 24 shows that an amplicon of 1516 bp corresponding to the Actin/LacZ 
primer set is produced from DNA prepared from all 3 brain areas from all the 82-hChAT 
mice and from three of the five 82-hChAT;NkCre mice. Since the internal primer is 
amplified in all samples tested, the lack of this amplicon in a subset of the 82-
hChAT;NkCre mice is not likely due to DNA quality. This amplicon was not produced 
by PCR amplification of DNA prepared from brain tissues of the WT mice. 
Figure 25 shows the results from the PCR reactions related to the Actin/ChAT 
primer set. Importantly, only the 82-hChAT;NkCre mice display an amplicon of 772 bp 
that corresponds to this primer combination, but, as was seen with the Actin/LacZ primer 
set, only three of five mice displayed this amplicon. The 772 bp amplicon was produced 
from DNA prepared from all 3 brain areas of these mice, with the greatest amplicon 
strength appearing in the basal forebrain. WT and 82-hChAT mice do not display this 
amplicon. It is predicted that an amplicon of 5710 bp be produced from DNA isolated 
from both 82-hChAT mice and 82-hChAT;NkCre mice but this was not observed.   
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Figure 19. 82-hChAT and 82-hChAT;NkCre mice contain the human 82-kDa ChAT 
gene in all brain areas. Successful development of transgenic mice containing the 
human 82-kDa ChAT gene is shown by presence of an amplicon of 199 bp corresponding 
to primers for the human 82-kDa ChAT gene in both 82-hChAT mice (n=3) and 82-
hChAT;NkCre mice (n=5). Wild-type (WT) mice (n=3) do not display this amplicon. 
Panels A, B, and C show that 82-hChAT and 82-hChAT;NkCre mice display this 
amplicon in cortex, striatum and basal forebrain, respectively. Panel D illustrates 
schematically the approximate location of the forward (F) and reverse (R) primers for 
PCR-based amplification of a portion of the hChAT sequence on the pcCALL2:82-ChAT 
sequence. 
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Figure 20. 82-hChAT;NkCre mice contain the gene for Cre recombinase within 
their genomic DNA. Successful development of a double transgenic mouse containing 
both human 82-kDa ChAT and Cre recombinase genes is shown by additional presence 
of an amplicon of 650 bp corresponding to primers for Cre recombinase in 82-
hChAT;NkCre mice (n=5). 82-hChAT (n=3) and wild-type (WT) mice (n=3) do not 
display this amplicon. All mice in all areas contain an amplicon of 89 bp corresponding 
to an internal control primer set. Panels A, B, and C show that 82-hChAT;NkCre mice 
display the Cre amplicon in cortex, striatum and basal forebrain, respectively. Panel D 
illustrates schematically the location at which Cre recombinase mediates LacZ excision.  
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Figure 21. The 82-hChAT and 82-hChAT;NkCre mice contain the IRES gene 
sequence within their genomic DNA. The pcCALL2:82-ChAT DNA sequence used to 
create the 82-hChAT transgenic mice contains the IRES gene, and a PCR amplicon 
corresponding to the IRES gene is detected in all 3 brain areas tested in 82-hChAT (n=3) 
and 82-hChAT;NkCre mice (n=5). PCR of DNA samples from the brain samples of WT 
mice (n=3) does not result in production of this amplicon. A PCR amplicon of 89 bp 
corresponding to an internal control primer set was produced in all DNA samples. Panels 
A, B, and C show genomic DNA extracted from the cortex, striatum and basal forebrain, 
respectively. Panel D provides a schematic of the approximate location of the forward 
(F) and reverse (R) IRES primers on the pcCALL2:82-ChAT sequence.  
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Figure 22. The 82-hChAT and 82-hChAT;NkCre mice contain the GFP gene 
sequence within their genomic DNA. The pcCALL2:82-ChAT DNA sequence used to 
create the 82-hChAT transgenic mice contains the GFP gene and a PCR amplicon 
corresponding to the GFP gene is detected in all 3 brain areas of 82-hChAT (n=3) and 82-
hChAT;NkCre mice (n=5). PCR of DNA samples from brain samples of WT mice (n=3) 
does not result in production of this amplicon. A PCR amplicon of 223 bp corresponding 
to an internal control primer set was produced in all DNA samples. Panels A, B, and C 
show genomic DNA extracted from the cortex, striatum and basal forebrain, respectively. 
Panel D provides a schematic of the approximate location of the forward (F) and reverse 
(R) GFP primers on the pcCALL2:82-ChAT sequence.  
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Figure 23. The 82-hChAT and 82-hChAT;NkCre mice contain the LacZ gene 
sequence within their genomic DNA. The pcCALL2:82-ChAT DNA sequence used to 
create the 82-hChAT transgenic mice contains the LacZ gene, and a PCR amplicon 
corresponding to the LacZ gene is detected in all 3 brain areas tested in 82-hChAT (n=3) 
and 82-hChAT;NkCre mice (n=5). PCR of DNA samples from brain samples of WT 
mice (n=3) does not result in production of this amplicon. A PCR amplicon of 223 bp 
corresponding to an internal control primer set was produced in all DNA samples. Panels 
A, B, and C show genomic DNA extracted from the cortex, striatum and basal forebrain, 
respectively. Panel D provides a schematic of the approximate location of the forward 
(F) and reverse (R) LacZ primers on the pcCALL2:82-ChAT sequence. 
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Figure 24. All 82-hChAT and three of five 82-hChAT;NkCre mice contain the gene 
segment between chicken β-actin and LacZ. PCR amplification using the Actin/LacZ 
primer set yielded an amplicon of 1516 bp in brain samples in DNA samples prepared 
from 3 brain areas from all 82-hChAT mice (n=3) and three of the five 82-hChAT;NkCre 
mice (n=5). PCR analysis from DNA from WT mice (n=3) and two of the five 82-
hChAT;NkCre mice do not yield this Actin/LacZ amplicon. A PCR amplicon of 223 bp 
corresponding to an internal control primer set was produced in all DNA samples. Panels 
A, B, and C show genomic DNA extracted from the cortex, striatum and basal forebrain, 
respectively. Panel D provides a schematic of the approximate location of the forward 
(F) and reverse (R) Actin/LacZ primers on the pcCALL2:82-ChAT sequence. 
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Figure 25. 82-hChAT;NkCre mice show successful excision of the floxed LacZ gene 
by Cre. PCR amplification of DNA prepared from brain tissues of three of the five 82-
hChAT;NkCre mice (n=5) yielded an amplicon of 772 bp corresponding to the 
Actin/ChAT primer set when the floxed LacZ gene is excised by Cre. It is predicted that 
a large amplicon (5710 bp) would be produced from DNA from both 82-hChAT and 82-
hChAT;NkCre mice, but this amplicon was not detected. PCR amplification of DNA 
preparations from WT mice (n=3), 82-hChAT mice (n=3) and two of the five 82-
hChAT;NkCre mice do not display this Actin/ChAT amplicon. All 82-hChAT;NkCre 
mice are expected to display this amplicon using the Actin/ChAT primer set. It was 
predicted that the amplicon strength would be greatest from DNA preparations from the 
basal forebrain (Panel C) of 82-hChAT;NkCre mice as compared to cortex (Panel A) and 
striatum (Panel B). Panel D shows a schematic of the approximate location of the 
forward (F) and reverse (R) Actin/ChAT primers on the pcCALL2:82-ChAT sequence. 
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Immunoblot analysis of human 82-kDa ChAT protein in brain tissue lysates 
 
I analyzed lysates of brain tissue by immunoblot to determine if the expression of 
82-kDa ChAT protein can be detected in 82-hChAT;NkCre mice that are transgenic for 
both Cre and human 82-kDa ChAT. Brains of mice were bisected along the midline, then 
cut coronally into 4 pieces (front, middle front, middle back and back). A representative 
immunoblot provided in Figure 26 indicates that the presence of 82-kDa ChAT was not 
revealed in any of the brain regions in WT, 82-hChAT or in 82-hChAT;NkCre mice 
using either the CTab or NTab antibodies that are specific to human ChAT. Human 82-
kDa ChAT protein was not detected in brain tissues of the WT, 82-hChAT or 82-
hChAT;NkCre mice even following over-exposure of the immunoblots (Figure 27). 
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Figure 26. Human 82-kDa ChAT is not detected in mouse brain lysates from 82-
hChAT;NkCre, 82-hChAT or WT mice by immunoblot. Aliquots of tissue lysate 
containing 100 µg of protein were loaded onto SDS-PAGE gels for electrophoresis. 
Immunoblots were probed with CTab anti-ChAT primary antibody (1:1,000) followed by 
goat anti-rabbit HRP-conjugated secondary antibody (1:10,000). The immunoblotting 
membranes were stripped and re-probed for NTab anti-ChAT primary antibody (1:200) 
followed by secondary antibody (1:10,000). The 82-kDa ChAT protein was not detected 
in any of the mouse brain tissue samples examined. The actin immunoblot was used as a 
control for sample protein loading. 
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Figure 27. Overexposure of immunoblots did not reveal the presence of 82-kDa 
ChAT protein in mouse brain samples. A representative blot is shown.  
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Human 82-kDa ChAT is expressed in brain areas where Nkx2.1-Cre mediates floxed 
LacZ gene excision  
 
To further examine if the 82-hChAT;NkCre mice express human 82-kDa ChAT 
protein, brain sections were stained with the NTab antibody that recognizes a specific 
epitope in the amino-terminus of human 82-kDa ChAT, followed by the addition of a 
fluorescently-tagged secondary antibody. An additional goal in these studies was to 
determine where in the mouse brain that the human 82-kDa ChAT protein is expressed. 
Importantly, it was found that staining for the human 82-kDa ChAT protein is limited to 
the 82-hChAT;NkCre mice (n=3) and was found predominantly in the basal forebrain 
areas, including diagonal band of Broca and medial septum, and in the medial cerebral 
cortex. The 82-hChAT mice (n=3) do not display specific staining for the human 82-kDa 
ChAT protein. Figure 28 shows images of coronal brain section from the 82-hChAT 
mouse and the 82-hChAT;NkCre mouse as well as an image from the mouse brain atlas 
indicating approximate location of the coronal slice. Human 82-kDa ChAT protein 
staining is shown in green.  
Finally, I assessed the distribution of human 82-kDa ChAT protein in the brain of 
the 82-hChAT;NkCre mice in comparison to the 82-hChAT mouse. The following 
figures show representative images of immune-positive staining for the 82-kDa ChAT 
protein in the diagonal band of Broca (Figure 29), medial septum (Figure 30), striatum 
(Figure 31), cerebral cortex near the midline (Figure 32) and cerebral cortex away from 
the midline (Figure 33) of 82-hChAT;NkCre mice. The 82-hChAT;NkCre mice display 
staining specific to human 82-kDa ChAT in the basal forebrain area, in both diagonal 
band of Broca and medial septum, as well as the medial cortex. Staining in these areas is 
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predominantly localized to nuclei of neurons as is evident in the merged images with the 
nuclear dye DAPI. The 82-kDa ChAT specific staining was not seen in the striatum or the 
lateral cortex of the 82-hChAT;NkCre brain. The 82-hChAT mice did not display 82-kDa 
ChAT specific staining in any brain areas, but occasional background staining was 
observed in some brain areas that was not specific to 82-kDa ChAT protein. 
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Figure 28. The 82-hChAT;NkCre mouse displays human 82-kDa ChAT staining in 
the basal forebrain (diagonal band of Broca (DBB), medial septum(MS)), as well as 
in the cerebral cortex along the midline. Human 82-kDa ChAT protein staining, seen 
as green dots, is evident in the 82-hChAT;NkCre mouse (n=3), but no such staining is 
present in the 82-hChAT mouse (n=3). Slides were stained with NTab at 1:1,000 and 
AlexaFluor 488 conjugated secondary antibody at 1:1,000. Arrows indicate areas where 
82-kDa ChAT protein staining is evident. The anterior commissure (AC) is indicated in 
the stained brain sections as well as in the image from a mouse brain atlas. Scale is 500 
µm.  
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Figure 29. The 82-hChAT;NkCre mice display human 82-kDa ChAT specific 
staining in the diagonal band of Broca area predominantly in the nuclei of neurons. 
Mouse brains were stained using the anti-human 82-kDa ChAT primary antibody NTab 
(1:1,000) (green) and counterstained using DAPI (blue) to identify nuclei. There is no 82-
kDa ChAT specific staining in 82-hChAT brains, while 82-kDa ChAT staining is evident 
in the 82-hChAT;NkCre mice predominantly localized to nuclei of neurons. The bright 
green staining evident in some images from 82-hChAT brains is not nuclear and 
corresponds to non-specific staining. The scale bars each represent 20 µm.   
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Figure 30. The 82-hChAT;NkCre mice display human 82-kDa ChAT specific 
staining in the medial septum area predominantly in the nuclei of neurons. Mouse 
brains were stained using the anti-human 82-kDa ChAT primary antibody NTab 
(1:1,000) (green) and counterstained using DAPI (blue) to identify nuclei. There is no 82-
kDa ChAT specific staining in 82-hChAT brains, while 82-kDa ChAT staining is evident 
in the 82-hChAT;NkCre mice predominantly localized to nuclei of neurons. The bright 
green staining evident in some images from 82-hChAT brains is not nuclear and 
corresponds to non-specific staining. The scale bars each represent 20 µm.   
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Figure 31. Neither 82-hChAT;NkCre mice nor 82-hChAT mice display human 82-
kDa ChAT-specific staining in the striatum of the brain. Mouse brains were stained 
using the anti-human 82-kDa ChAT primary antibody NTab (1:1,000) (green) and 
counterstained using DAPI (blue) to identify nuclei. There is no 82-kDa ChAT specific 
staining in the striatum of either 82-hChAT brains or 82-hChAT;NkCre brains. The 
bright green staining evident in some images from 82-hChAT brains is not nuclear and 
corresponds to non-specific staining. The scale bars each represent 20 µm.   
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Figure 32. The 82-hChAT;NkCre mice display human 82-kDa ChAT specific 
staining in the cortex near the midline predominantly in nuclei of neurons. Mouse 
brains were stained using the anti-human 82-kDa ChAT primary antibody NTab 
(1:1,000) (green) and counterstained using DAPI (blue) to identify nuclei. There is no 82-
kDa ChAT specific staining in 82-hChAT brains, while 82-kDa ChAT staining is evident 
in the 82-hChAT;NkCre mice predominantly localized to nuclei of neurons. The bright 
green staining evident in some images from 82-hChAT brains is not nuclear and 
corresponds to non-specific staining. The scale bars each represent 20 µm.  
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Figure 33. Neither 82-hChAT;NkCre mice nor 82-hChAT mice display human 82-
kDa ChAT specific staining in the cerebral cortex lateral to the midline of the brain. 
Mouse brains were stained using the anti-human 82-kDa ChAT primary antibody NTab 
(1:1,000) (green) and counterstained using DAPI (blue) to identify nuclei. There is no 82-
kDa ChAT specific staining of either 82-hChAT brains or 82-hChAT;NkCre brains in the 
lateral cerebral cortex. The scale bars each represent 20 µm.   
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CHAPTER 4: DISCUSSION 
 
1. Significant Findings 
 
The goal of the studies that comprise this thesis was to characterize the expression 
of human 82-kDa ChAT from a pcCALL2 vector-based plasmid in both cell-based and in 
vivo models. Previous studies from our laboratory demonstrate that the 82-kDa ChAT 
protein is localized predominantly in nuclei of neurons (Resendes et al. 1999, Gill et al. 
2003, 2007), and that it can be found in cholinergic neurons in necropsy human brain and 
spinal cord (Gill et al. 2007). A critical recent finding is that expression of 82-kDa ChAT 
protein in neurons leads to altered expression of genes involved in a number of cellular 
functions (Albers et al. 2014). Of significance in that study is that several genes for 
proteins that regulate the amyloidogenic processing of amyloid precursor protein (APP) 
are differentially regulated in neurons expressing this nuclear form of human ChAT. The 
altered pattern of expression of these proteins in 82-kDa ChAT expressing neurons, such 
as a decrease in β-secretase levels and activity, results in decreased amyloidogenic APP 
processing and a decrease in β-amyloid production (Albers et al. 2014). It was also 
reported by Matsuo and colleagues that expression of 82-kDa ChAT in neural cells 
altered expression of genes for the high-affinity choline transporter CHT (Matsuo et al. 
2011). To our knowledge, all research to date investigating the functional roles of 82-kDa 
ChAT and its potential protective role in Alzheimer’s disease has been conducted in 
vitro. Therefore, the importance of the studies carried out for this thesis stems from the 
need to assess the function of this nuclear form of human ChAT in an in vivo model. 
Thus, a recombinant DNA plasmid encoding full-length human 82-kDa ChAT was 
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prepared to be used for pronuclear injections, and founder transgenic mice were produced 
to conditionally express human 82-kDa ChAT under the control of Nkx2.1-driven Cre 
recombinase expression in specific forebrain neurons, with these characterized in this 
thesis.  
I demonstrate first in cell-based experiments that the pcCALL2 vector-based 
plasmid encoding human 82-kDa ChAT, termed pcCALL2:82-ChAT, can express the 
protein driven by Cre recombinase-mediated excision of a floxed LacZ gene contained 
within the sequence. The pcCALL2 vector takes advantage of the Cre-LoxP system to 
allow conditional expression of a transgenic protein in selected tissues or cells that are 
induced to express Cre recombinase. I confirmed, through examination of cellular DNA 
that excision of the LacZ gene occurred with the co-transfection of a Cre-expressing 
plasmid. Additionally, by PCR amplification of cellular DNA using primer sets specific 
to human 82-kDa ChAT and other sequence elements of the pcCALL2 vector, I showed 
that the human ChAT gene and other gene elements specific to the pcCALL2 vector are 
present in the cells transfected with pcCALL2:82-ChAT. This indicates that the human 
82-kDa ChAT sequence was successfully ligated into the original pcCALL2 vector, and 
is added to the cellular DNA pool. Protein expression of both LacZ and ChAT was also 
examined and it was determined that with the co-expression of Cre, I not only see the loss 
of or decrease in LacZ expression, but also the expression of human 82-kDa ChAT.  
I was also able to show that in vivo expression of human 82-kDa ChAT protein is 
dependent on Cre-mediated excision of the floxed LacZ gene and that this occurs 
predominantly in regions in which the Nkx2.1 promoter is reported to drive Cre 
recombinase activity (Xu et al. 2008). Analysis of genomic DNA from different brain 
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regions of the 82-hChAT;NkCre mice revealed that in the basal forebrain, where Nkx2.1 
is known to be expressed and mediate Cre recombinase activity in the Nkx2.1-Cre-driver 
mice, the presence of amplicons specific to a chicken β-actin/ hChAT (Actin/ChAT) 
primer set were detected, with amplicon intensity being less in other brain areas. While I 
did not detect 82-kDa ChAT protein by immunoblot, immunocytochemistry revealed that 
the protein was expressed and localized primarily to nuclei of neurons and found 
predominantly in the basal forebrain area, including the medial septum and diagonal band 
of Broca. While expression of the protein was not exclusive to the basal forebrain, this is 
where the predominant staining was found. 
Thus, I was able to provide evidence that the expression of human 82-kDa ChAT 
from the pcCALL2:82-ChAT plasmid is dependent on the activity of Cre recombinase 
both in cell-based studies and in vivo in transgenic mice.  
 
2. Discussion of Results 
 
Expression of Cre recombinase attenuates LacZ gene expression 
 
The overall objective of this thesis was to examine the expression of human 82-
kDa ChAT derived from the pcCALL2:82-ChAT plasmid and how this expression is 
mediated through the co-expression of Cre recombinase in both cultured cells and a 
mouse model. To test my hypothesis, it was necessary to examine the DNA extracted 
from cells and mouse brains to determine the presence of Cre recombinase.  
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PCR primer sets were designed that are specific to a number of elements found in 
the modified pcCALL2:82-ChAT plasmid, such as IRES, LacZ, GFP and human 82-kDa 
ChAT. It was determined that the first three were present in all cells transfected with 
either pcCALL2 vector or the pcCALL2:82-ChAT plasmid, whereas the latter one was 
only present in cells transfected with the pcCALL2:82-ChAT plasmid. This result is 
promising in that it indicates that the generation of the recombinant DNA construct that 
encodes the human 82-kDa ChAT gene was successful.  
I predicted that if Cre recombinase is co-expressed in cells with the floxed LacZ 
containing plasmids, then LacZ may be excised and a decrease in the LacZ gene PCR 
amplicons could indicate successful excision of the LacZ gene by Cre recombinase. The 
results obtained for this measure indicate fairly equal levels of LacZ amplicon intensity. 
Potential explanations for this finding are that: (1) the PCR protocol used is not 
quantitative and may not adequately reveal changes in template amounts, (2) transfection 
and co-transfection of the two plasmids may differ between the cell groups thereby not 
allowing direct comparison of differences, particularly for the large plasmids pcCALL2, 
pcCALL2:82-ChAT and pcAGGS nls Cre plasmids or (3) the amount of total floxed 
LacZ-containing DNA sequences is considerably greater than those in which LacZ has 
been excised leading to an indistinguishable difference in the amount of PCR amplicons 
generated.  
The two most informative PCR primer sets used to examine DNA extracted from 
the cells or brain tissues were the chicken β-actin/LacZ (Actin/LacZ) and chicken β-
actin/ChAT (Actin/ChAT) sets. In cells co-transfected with either the pcCALL2 vector or 
the pcCALL2:82-ChAT plasmid and the Cre-expressing plasmid, a complete or partial 
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excision of the floxed LacZ gene should be seen as a decrease in Actin/LacZ PCR 
amplicon strength. In the PCR analysis of the cellular DNA, a decrease in the Actin/LacZ 
amplicon strength was seen, thereby giving the promising results that the floxed LacZ 
gene in the original vector and 82-kDa ChAT sequence containing plasmid can undergo 
excision in the presence of Cre recombinase activity.  
The Actin/ChAT primer combination should yield a large amplicon (5710 bp) 
corresponding to cells transfected with pcCALL2:82-ChAT only in the absence of Cre 
recombinase, and a small amplicon (772 bp) in cells where Cre has excised the floxed 
LacZ gene from the pcCALL2:82-ChAT plasmid sequence. The presence of a large PCR 
amplicon was not detected in DNA prepared from either cells transfected with the 
pcCALL2:82-ChAT plasmid or cells co-transfected with the pcCALL2:82-ChAT and the 
Cre-expressing plasmid, as this amplicon size is likely too large to be amplified with the 
PCR conditions used in these experiments. However, in a critical experiment, PCR 
analysis of DNA prepared from cells co-expressing both pcCALL2:82-ChAT and Cre 
with the Actin/ChAT primer set did reveal the expected amplicon of 772 bp. This 
promising result demonstrated that the Cre-mediated excision of the floxed LacZ gene is 
successful in cells that are co-transfected with the Cre-expressing plasmid. The same 
PCR product of 772 bp is observed with genomic DNA isolated from brain areas of the 
Tg 82-kDa hChAT;Nkx2.1-Cre (82-hChAT;NkCre) mice, and this confirms excision of 
the floxed LacZ gene from the pcCALL2:82-ChAT plasmid used to generate the 
transgenic mice when the mice are crossed with the Cre-driver mice. Importantly, as 
expected, this 772 bp PCR product is not obtained when genomic DNA prepared from 
the Tg 82-kDa hChAT (82-hChAT) mice is analyzed with the Actin/ChAT primer set.  
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Analysis of genomic DNA prepared from WT, 82-hChAT and 82-hChAT;NkCre 
mice yielded similar results to those seen in transfected cultured cells. It was found that 
PCR analysis of genomic DNA prepared from both groups of transgenic mice yield 
amplicons of the correct size pertaining to IRES, GFP and LacZ, in all brain areas. In 
terms of LacZ, it was expected that a decrease in amplicon strength in the basal forebrain 
may be seen, indicating the Cre-mediated excision of this floxed gene by Nkx2.1-Cre. 
However, this was not observed, perhaps indicating that the number of cells under the 
direction of Nkx2.1-Cre in the basal forebrain is small and that this excision of the floxed 
LacZ gene cannot be detected by the semi-quantitative PCR method used in these 
experiments. In two of the five DNA samples prepared from the 82-hChAT;NkCre mice, 
there is a decrease in amplicon strength with this primer set when compared to the other 
strains of mice, but this was not specific to the basal forebrain, and as will be discussed 
further, several differences were observed with analysis of the genomic DNA prepared 
from these two mice.  
Analysis of the genomic DNA prepared from the three strains of mice by PCR 
utilizing the primer sets specific for human 82-kDa ChAT show that this gene sequence is 
present in both the 82-hChAT and 82-hChAT;NkCre mouse models developed, but not in 
the WT mice. In the case of the 82-hChAT;NkCre mice, we also see presence of a PCR 
amplicon pertaining to the Cre primer set, further classifying these mice as double 
transgenic.  
The PCR analysis of the mouse genomic DNA using the primer sets Actin/LacZ 
and Actin/ChAT is important when studying different brain areas. It was predicted and 
observed that amplicons corresponding to the Actin/LacZ primer set are produced by 
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PCR of genomic DNA isolated from all three brain areas studied from 82-hChAT mice. It 
was also predicted that the Actin/LacZ amplicon would be produced by PCR of genomic 
DNA isolated from the three brain areas studied from the 82-hChAT;NkCre mice, with a 
possible decrease in amplicon abundance in samples from the basal forebrain. However, a 
decrease in the amplicon abundance was not found, indicating once again that the number 
of cells which express Nkx2.1-Cre are low and semi-quantitative PCR is not sufficient to 
reveal these differences. Again, two of the five mice do not display an amplicon 
corresponding to the Actin/LacZ primer set. However, this is not likely due to PCR 
failure as the internal primer was amplified from all mice and all brain areas.  
Finally, the presence of an amplicon corresponding to the Actin/ChAT primer set 
was found with the PCR amplification of genomic DNA samples from basal forebrain of 
three of the five 82-hChAT;NkCre mice sampled. This amplicon was also produced by 
PCR amplification of genomic DNA isolated from samples of cerebral cortex and 
striatum of these same 3 mice, but the amplicon abundance appeared to be less when 
compared to that for the basal forebrain. This is a critical result as it was predicted that 
this amplicon would be produced from genomic DNA following the excision of the 
floxed LacZ gene by Cre recombinase, and it would be seen in areas where Nkx2.1-Cre 
mediated this excision. Observing this amplicon as a stronger band in the basal forebrain 
samples shows potential for these double transgenic mice as other research has shown 
that the Nkx2.1 transcription factor is expressed predominantly in cholinergic neurons in 
this brain area. However, it is necessary to confirm this promising result using 
quantitative approaches.  
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Interestingly, two of the five 82-hChAT;NkCre mice did not yield results that 
were consistent with the other three 82-hChAT;NkCre mice, and the results obtained are 
not consistent with what is expected based on the analysis of DNA in the cell-based 
studies. The only known difference with these two mice as compared to the other three 
mice is they come from different lineages with the original mating pairs of the Cre-
expressing and the 82-hChAT mice that yielded these mice being different. The three 
mice resulted from the mating of a Cre-expressing female and an 82-hChAT male, while 
the other 2 mice were the opposite. While it was shown that all five of the 82-
hChAT;NkCre mice are double transgenic for both Cre and hChAT, the reasoning for 
lack of production of a PCR amplicon for both Actin/LacZ and Actin/ChAT primer sets 
is unclear. It is possible that the transmission of the Nkx2.1-Cre is different and therefore 
there is a lower level of excision of the floxed LacZ gene in fewer cells in the brain. 
However, this would mean that I would still see an amplicon corresponding to the 
Actin/LacZ primer combination. One possible explanation could be the phenomenon of 
genomic imprinting. This is an epigenetic phenomenon by which certain genes are 
expressed depending on the parent-of-origin. Since the original parents for the two 
double transgenic mice compared to the other three were different, it is possible that the 
transmission of expression is dependent on the one parental combination over the other 
(Peters 2014). 
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LacZ protein is decreased with the addition of Cre recombinase 
 
Examination of the excision of the floxed LacZ gene by Cre was further assessed 
by staining of HEK 293 cells that were transiently transfected with various plasmid 
combinations using a LacZ Tissue Staining Kit. Cells that exhibit a blue colour with this 
staining protocol indicate that the LacZ gene is expressed and translated to produce the β-
galactosidase (β-gal) enzyme. Cells transfected with a pcDNA3.1 vector-based plasmid to 
express either human 69-kDa ChAT or 82-kDa ChAT do not exhibit blue staining as the 
pcDNA3.1 vector does not contain the LacZ gene. These cells were used as controls that 
express ChAT protein, but not LacZ. Separate sets of cells that were transfected with the 
pcCALL2 vector or the pcCALL2:82-ChAT plasmid exhibit strong blue staining, 
indicating expression of the LacZ gene and the subsequent production of β-gal. These 
results show that these constructs are transfected into cells and that the elements on the 
vector are able to be expressed.  
Those cells co-transfected with the Cre-expressing plasmid in conjunction with 
either the pcCALL2 vector or the pcCALL2:82-ChAT plasmid exhibit a greatly reduced 
blue staining when compared to cells that were transfected with the pcCALL2 vector-
based plasmids in the absence of Cre. The pcCALL2 vector takes advantage of the Cre-
LoxP system for the excision of the floxed LacZ gene by Cre recombinase to be able to 
facilitate conditional cell and tissue specific expression of a transgene, and therefore cells 
expressing both the pcCALL2 and Cre-expressing vectors should not develop a blue 
colour. Again, as discussed for PCR analysis of cellular DNA, the transfection efficiency 
of these two large plasmids may be low. It is possible that the cells that are not stained 
blue are non-transfected cells or cells that are only transfected with the pcAGGS nls Cre 
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plasmid. However, using the same argument, there may also be cells incorporating only 
the pcCALL2 vector or the pcCALL2:82-ChAT plasmid and these would be expected to 
exhibit strong blue staining. While some blue stained cells are seen in the two groups of 
cells co-transfected with the pcCALL2 vector-based plasmids and the Cre-expressing 
plasmid, the blue staining is rather weak and limited to a few cells. It is predicted that if 
there are more cells expressing only the pcCALL2 vector-based plasmids, then there 
would be greater number of intensely blue stained cells. Taken together, these results 
give a promising indication that the pcCALL2:82-ChAT plasmid is active in that we see 
Cre recombinase-mediated excision of the floxed LacZ gene. It is predicted that similar 
findings would be achieved in vivo.  
 
Human 82-kDa ChAT expression is mediated by Cre recombinase excision of LacZ 
 
It is predicted that without the Cre recombinase-mediated removal of the floxed 
LacZ gene from the pcCALL2:82-ChAT plasmid, the expression of 82-kDa ChAT does 
not occur due to the length of the sequence between the plasmid promoter and the hChAT 
sequence and the presence of an intervening STOP codon following the LacZ gene. To 
determine this, I assessed expression of human 82-kDa ChAT protein in cells transfected 
with the pcCALL2:82-ChAT plasmid in either the presence or the absence of Cre-
expressing plasmid by immunoblot.  
An important observation is that immunoblots of cell lysates probed with either 
the CTab or NTab anti-hChAT antibody revealed that 82-kDa ChAT protein is detectable 
in cells co-transfected with the pcCALL2:82-ChAT plasmid and the Cre-expressing 
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plasmid. It was predicted that the analysis of brain tissues by immunoblot would reveal 
expression of human 82-kDa ChAT protein in brain areas where Nkx2.1 transcription 
factor would mediate Cre recombinase expression, including relatively stronger 
expression in basal forebrain. However, analysis of brain tissue lysates by immunoblot 
did not reveal the presence of the protein in any brain areas tested. This may reflect a lack 
of sensitivity of the methods used, low levels of expression of the human 82-kDa ChAT 
protein, or non-specific banding patterns of the antibodies employed decreasing ability to 
discern the specific immunopositive protein of interest. For example, on immunoblots 
using the CTab antibody, an intense immunopositive band appears around 100 kDa that 
may mask a potential band at 82 kDa when blots are over-exposed, thus making the 
detection of a protein at this level difficult. A preliminary experiment to 
immunoprecipitate 82-kDa ChAT from brain tissue lysate did not yield positive results.  
 
Human 82-kDa ChAT is expressed predominantly in nuclei and predominantly in 
areas driven by Nkx2.1-Cre activity 
 
Excision of the floxed LacZ gene by Cre recombinase is expected to allow the 
expression of human 82-kDa ChAT from the pcCALL2:82-ChAT plasmid. This excision, 
in the double transgenic 82-hChAT;NkCre mouse is expected to occur in regions where 
Cre recombinase expression is driven by the Nkx2.1 promoter. As mentioned previously, 
Nkx2.1 is a protein that regulates transcription of genes that are essential for prenatal 
development of forebrain neurons and postnatal maturation and maintenance of 
cholinergic basal forebrain neurons (Magno et al. 2011). Therefore, it is expected that 
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mice would express human 82-kDa ChAT in brain regions under the control of Nkx2.1, 
such as the basal forebrain.  
A critical finding is that when HEK 293 cells that have been co-transfected with 
the pcCALL2:82-ChAT plasmid and Cre-expressing plasmid then immunostained for 
CTab, expression of the 82-kDa ChAT protein is confirmed. This is not observed in cells 
that are co-transfected with the pcCALL2 vector and Cre-expressing plasmid, or when 
cells are transfected with the pcCALL2 vector or the pcCALL2:82-ChAT plasmid in the 
absence of Cre, thus confirming the requirement for co-expression of Cre recombinase 
with pcCALL2:82-ChAT.  
In the mouse brain, I observed that in the double transgenic 82-hChAT;NkCre 
mice the human 82-kDa ChAT protein is localized predominantly to nuclei of neurons 
and is expressed mostly in the basal forebrain (medial septum and diagonal band of 
Broca) region of the brain. Some staining is also found in the cerebral cortex of these 
mice, but, since expression of Nkx2.1 transcription factor is predominantly in basal 
forebrain, but not limited to this region, staining outside of the basal forebrain is 
expected. The staining of brain sections from 82-hChAT mice are an important control in 
this study, and it was found that expression of human 82-kDa ChAT protein is limited to 
the 82-hChAT;NkCre mice. 
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3. Limitations of Experimental Work 
 
The major limitation in the present research was the availability of sufficient 
numbers of both 82-hChAT and 82-hChAT;NkCre mice. While mice were constantly 
being mated and pups being produced, the proportion of transgenic animals in 
comparison to non-transgenic was low, particularly for the double transgenic 82-
hChAT;NkCre mice. Some litters had only a single, or even no, transgenic mice. This 
severely limited the number of experiments and replicate samples that could be 
performed. 
As mentioned above, a limitation to the cell-based studies was the transfection 
efficiency of the pcCALL2 vector and the pcCALL2:82-ChAT plasmid. Since these 
recombinant DNA constructs are comparatively large (~11000 bp for pcCALL2 and 
~13000 bp for pcCALL2:82-ChAT), the proportion of cells which were transfected or co-
transfected may have been quite low and could potentially provide different results in 
comparison with observations from the in vivo transgenic mouse model.  
Lastly, a limitation may be associated with cells only expressing the transfected 
plasmids for 48 h prior to DNA being isolated for analysis. With this short time point, it 
is unlikely that all plasmid DNA would be incorporated into genomic DNA of the cells, 
thus the DNA isolated from the cells would be a combination of genomic DNA and 
plasmid DNA from transfection. To ensure that these cells are expressing the sequences 
in their DNA, it would be better to establish stably-transfected cell lines and then use 
DNA isolated from these cells for the PCR analysis. However, isolating stable 
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transformants is very time consuming and could not be accomplished within the scope of 
this thesis. 
 
4. Significance of this Research 
 
Alzheimer’s disease (AD) is the most common degenerative neurologic disorder 
associated with aging and is characterized by memory deficits and decreases in cognitive 
function. It has been found that atrophy of the basal forebrain brain region is a pre-
symptomatic marker for AD, making this particular brain area important in the study of 
the disease (Hall et al. 2008). Our laboratory has found that the presence of human 82-
kDa ChAT in nuclei of neurons may play a neuroprotective role by decreasing the 
amyloidogenic APP processing pathway and reducing the production and release of β-
amyloid peptides from neurons (Albers et al. 2014). Therefore, the expression of human 
82-kDa ChAT specifically in the basal forebrain region of the brain may provide a degree 
of protection against AD onset and progression.  
The importance of Nkx2.1 in this study is that this transcription factor is essential 
for the post-natal maintenance and maturation of cholinergic basal forebrain neurons, the 
very neurons that experience dysfunction in AD (Magno et al. 2011). If it is indeed the 
case that human 82-kDa ChAT confers a degree of protection against AD, then targeting 
the expression of this protein specifically to the basal forebrain area provides an excellent 
model in which to perform in vivo work related to AD.  
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This thesis is therefore instrumental in future work conducted using this 82-
hChAT;NkCre mouse model. Characterization of this model is necessary to determine 
whether the model is working as expected, and more specifically whether Nkx2.1-Cre 
recombinase is driving the expression of human 82-kDa ChAT to the basal forebrain 
region.  
 
 
5. Future Studies and Directions 
 
The experiments reported in this thesis provide characterization of the 
pcCALL2:82-ChAT plasmid and the transgenic mouse model that is derived from its 
sequences. I have shown that with the co-expression of Cre recombinase, excision of the 
floxed LacZ gene takes place and I was able to demonstrate that this corresponds with 
expression of human 82-kDa ChAT protein, a finding that does not occur in absence of 
Cre. I also show that in the double transgenic 82-hChAT;NkCre mice the human 82-kDa 
ChAT protein is localized predominantly to nuclei of neurons in the basal forebrain 
region, although some of this protein is expressed in other brain areas. While the initial 
characterization of the transgenic mouse model has been performed in this thesis, 
considerably more studies are necessary before this can be a considered to be a viable 
model used in AD research.  
First, a comprehensive analysis of the localization of human 82-kDa ChAT 
throughout the brain should be carried out. While the Nkx2.1 transcription factor is 
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expressed predominantly in the basal forebrain, there are reports of it being expressed 
elsewhere in the brain, such as in the hypothalamus, olfactory bulb, and medial 
amygdala. Moreover, in addition to expression of Nkx2.1 in the brain, this transcription 
factor can also be expressed in the thyroid and lung. Therefore, assessing expression of 
82-kDa ChAT in these other tissues is required and will add to the current knowledge of 
Nkx2.1 expression. Additionally, since AD is associated with the dysfunction of 
cholinergic neurons, it is necessary to determine the extent to which the human 82-kDa 
ChAT transgenic protein is localized to cholinergic neurons. By co-staining brain 
sections with a known marker for cholinergic neurons, such as the high-affinity choline 
transporter (CHT), co-localization of 82-kDa ChAT in cholinergic neurons can be 
determined. While Nkx2.1 will likely drive 82-kDa ChAT expression to neurons that do 
not have a cholinergic phenotype, it is necessary to determine to what extent these mice 
demonstrate cholinergic neuron co-localization. Staining of brain areas using a β-gal 
specific antibody may also give greater understanding of the Nkx2.1 expression pattern 
since in areas without Nkx2.1 driving Cre recombinase, the expression of LacZ would 
still be present. The limitation with this study is that if Nkx2.1 expression is very low, the 
β-gal expression may mask the areas and specific cells in which the 82-kDa ChAT 
protein may be present. 
Another important future step is to continue to troubleshoot the analysis of 82-
kDa ChAT protein expression in the brains by immunoblot and immunoprecipitation. It 
may be necessary that brains areas be dissected into smaller, more specific cholinergic 
neuron-rich areas with tissues being pooled from multiple mice to obtain sufficient 
protein that human 82-kDa ChAT could be detected. While this was not possible in this 
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thesis due to a shortage of mice, when the colony is more established in the future, this 
experiment should be revisited at a greater protein concentration.  
While analysis of genomic DNA was performed in this thesis, another alternative 
to examining gene expression is by analyzing mRNA from different brain areas by qRT-
PCR. Analyzing the presence of mRNA transcripts may give a better indication of the 
expression of human 82-kDa ChAT in different regions of the mouse brain and provides 
a more sensitive detection method than immunoblotting. Another possible method of 
examining mRNA transcripts in the different regions of the brain is by in situ 
hybridization.  
An additional experiment that was not performed in this thesis but is necessary for 
the further characterization of the mice is looking at the copy number of the transgene in 
the transgenic animals. The transgene copy number can greatly influence the expression 
level and the genetic stability of the target gene making knowledge of this number very 
important.  
Lastly, examination of behaviour of 82-hChAT;NkCre mice is another area of 
characterization that should be performed. While mice do not naturally get AD, there are 
mice, such as the double transgenic APP-PS1 AD model mice that exhibit an increased 
accumulation of Aβ beginning at 4 months of age with the formation of Aβ plaques by 6 
months of age. Behavioural studies comparing the 82-hChAT;NkCre mice with the APP-
PS1 mice will provide greater understanding of both double transgenic mice. A very 
important application of the 82-hChAT;NkCre mice would come from the crossing of 
these mice with the APP-PS1 mice. Based on our studies to date (Albers et al. 2014), it is 
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predicted that by crossing of these two strains of mice, there will be an attenuation or 
decrease in the accumulation of Aβ plaques in the basal forebrain area compared to the 
APP-PS1 mice. Behavioural and neurochemical analysis of the APP-PS1 mice, 82-
hChAT;NkCre mice and the APP-PS1 x 82-hChAT;NkCre mice will be immensely 
helpful in furthering our knowledge.  
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